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Prevalence of type 2 diabetes and its associated renal complications
Over the past decades it has been obvious that the prevalence of type 2 diabetes is increasing 
rapidly.(1) The World Health Organization reports that 346 million people suffer from diabetes and 
estimates indicate that the number of people with diabetes will double in 2030. Type 2 diabetes 
significantly contributes to morbidity, premature mortality and places a large burden on national 
health care budgets.
Patients with type 2 diabetes frequently present renal problems starting with sign of 
hyperfiltration followed by microalbuminuria (>30 mg of albumin in the urine per 24hr). The 
presence of microalbuminuria may be present in approximately 20 to 30% of all patients with type 
2 diabetes at the time of diagnosis. The progression to further involvement in the kidneys is shown 
when urinary albumin excretion rises to macroalbuminuria (> 300 mg/24hr) which occurs annually 
in approximately 3% of the microalbuminuric patients. Patients with macroalbuminuria are at risk 
for progressive renal function decline and loss of hormonal functions that are regulated by the 
kidneys such as vitamin D metabolism and erythropoietin production. Between 10 and 20% of all 
people with diabetes will ultimately require dialysis or transplantation if they did not prematurely 
die due to cardiovascular diseases. Given the high prevalence of diabetes and nephropathy in 
combination with the poor prognosis of these patients it is essential to optimize the use of currently 
available therapies as well as finding novel therapies. 
Effects of Angiotensin Receptor Blockers in patients with type 2 diabetes and nephropathy
Blood pressure lowering unambiguously contributes to reduce the risk of progressive renal function 
loss in patients with diabetes. During the last decades a vivacious debate has been ongoing on the 
topic which antihypertensive drugs to use to halt the progressive loss of renal function. Already 
in 1992 Bjorck et al showed that agents intervening in the renin-angiotensin-aldosterone-system 
(RAAS) more effectively reduce the risk of nephropathy than B-blockade.(2) Two years later 
the Angiotensin Converting Enzyme Inhibitor (ACEI) captopril was shown to reduce the risk of 
doubling of serum creatinine or End Stage Renal Disease (ESRD) in type 1 diabetic patients.(3) 
These early trials provided the first evidence of the clear beneficial effects of RAAS blockade. 
The introduction of Angiotensin Receptor Blockers (ARBs), which inhibit the activity of the 
RAAS by blocking the Angiotensin Type 1 Receptor, provided the possibility to further study the 
renoprotective effects of RAAS-inhibition in type 2 diabetic patients. The ROADMAP and IRMA-
2 trials have shown the value of ARBs in early stages of renal disease and demonstrated that 
olmesartan or irbesartan delayed the onset of micro- and macroalbuminuria, respectively.(4, 5) The 
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RENAAL and IDNT trials demonstrated that ARB treatment (losartan or irbesartan) in patients with 
type 2 diabetes and established nephropathy reduced the incidence of doubling serum creatinine 
concentration and ESRD.(6, 7)
The superior effects of RAAS-blockade with ACEIs or ARBs appeared to be related to 
their albuminuria lowering effects. High albuminuria has consistently been demonstrated to be 
one of the most important risk markers for ESRD in a range of patients and settings. Intervention 
in the RAAS with ACEi or ARB reduces albuminuria by approximately 30 to 40%.(8) The 
reduction in albuminuria obtained in the first months of therapy appears to be related with the 
progression of renal disease in the subsequent years. This observation was initially found in type 
2 diabetic and non-diabetic patients.(9, 10) Detailed post-hoc analyses from large scale clinical 
trials subsequently confirmed these findings in larger international cohorts and showed that the 
reduction in albuminuria in the first 6 months is linearly related with the risk reduction for ESRD. 
Interestingly, the reduction in albuminuria during ARB treatment, rather than the reduction in blood 
pressure, appeared to be the driving determinant for renoprotection in these trials.(11, 12) Thus, 
although ARBs are registered as antihypertensive drugs they appear to have off-target effects, such 
as albuminuria lowering, that contribute to their beneficial effects on clinical meaningful endpoints. 
This means that one should not only look at the on-target blood pressure effect to estimate the 
renoprotective effect, but also take the off-target anti-albuminuric effects into account.
Multiple off-target effects of Angiotensin Receptor Blockers
Apart from the blood pressure and albuminuria lowering effects of ARBs, these drugs have more 
off-target effects on renal risk markers. Blocking the RAAS has been shown to increase serum 
potassium as a result of decreased aldosterone activity.(13) Furthermore, it is known that some 
ARBs decrease serum uric acid.(14) Finally, it is known that RAAS-inhibition reduces hemoglobin 
levels possibly due to inhibition of erythropoiesis.(15) Since serum potassium, uric acid, and 
hemoglobin are independent risk markers for renal disease,(16, 17) ARB induced changes in these 
renal risk markers may influence the ultimate effect of ARBs on hard renal outcomes. 
Drug registration and development
To register a new drug in renal and cardiovascular disease the drug must be proven to be effective 
and safe. To prove the drug’s efficacy and safety, the on-target effects on the parameter of interest 
(e.g. blood pressure for antihypertensive drug or glucose for oral glucose lowering drug) are 
determined and used to estimate the potential long-term renal protection. To verify the estimated 
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long-term renal protection, the short-term evaluation is followed by a hard-outcome study looking 
at meaningful outcomes such as dialysis or renal transplantation. The latter thus requires large 
and expensive randomized controlled clinical trials with long-term follow-up. Several recent 
examples in renal and cardiovascular disease illustrate the failure of this process. Rosiglitazone 
was registered in Europe in 2000 based on its beneficial effect on HbA1c. However, meta-analyses 
have shown that, despite the HbA1c lowering effect, the drug increases cardiovascular risk leading 
to marketing suspension in 2010.(18, 19) In addition, the combination of an ACEi and ARB more 
effectively lowered blood pressure than the single use of these agents but increased renal risk in 
the ONTARGET trial.(20) These examples, and many others exist, indicate that the drugs did not 
deliver what they were intended to do estimated from their effects on the parameters of interest. 
Thus, only evaluating drug effects on the on-target risk factor is insufficient to estimate the ultimate 
drug effect on hard outcomes. It is likely that establishing the integrated effect of a drug on the 
on-target and off-target risk markers will result in a better prediction of drug effects on hard renal 
outcomes. Such an approach has obviously major consequences for drug benefit-risk assessment, 
cost of drug development, drug innovation and for society.
Aim of the thesis
To assess off-target effects of Angiotensin Receptor Blockers on renal risk markers in patients 
with type 2 diabetes and nephropathy and the relationship between off-target drug responses and 
effects on hard renal outcomes. This should ultimately result in the construction and validation of a 
multiple parameter risk response score based on on-target and off-target effects of ARBs in order to 
better estimate long-term drug efficacy. 
Chapter 2 reviewed the off-target effects of various drugs in patients with type 2 diabetes. 
This review focused on the relationship between the off-target effects of various drugs on novel 
risk markers and their relationship with renal and cardiovascular outcome in patients with diabetes. 
In chapter 3 the effect of losartan was assessed on a well-known but emerging risk marker in the 
renal arena, namely serum uric acid. In this study the magnitude of the reduction in serum uric 
acid induced by losartan was associated with the degree of renal protection and the contribution 
of the change in serum uric acid to the renoprotective effect of losartan was calculated. Chapter 
4a describes a similar analysis as described in chapter three and focused on the losartan induced 
change in serum potassium and its relationship with renal outcome. Importantly, the change in 
serum potassium induced by a drug is commonly considered a safety issue. However, this chapter 
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shows that a drug induced increase in serum potassium also affects drug’s renal outcome. This 
implies that one should not only evaluate the effect of a drug on serum potassium within the 
“safety” context but it should also be considered in drug efficacy evaluation. In chapter 4b the 
effects of the ARB losartan on serum potassium is further investigated in individual patients. The 
general believe is that within a patient the drug response in multiple parameters is concordant. This 
implies that a reduction in blood pressure is always accompanied by a reduction in albuminuria 
or an increase in serum potassium. However, recent studies have questioned this dogma and have 
shown that the effect of a drug on multiple risk markers is not always concordant within a patient. 
More specifically, ARBs may decrease blood pressure but at the same time increase albuminuria 
or vice versa within a patient. As both the change in blood pressure and the change in albuminuria 
predict long-term renoprotection, such data support a dual strategy of both targeting and optimizing 
the blood pressure and albuminuria response. In chapter 4b the response to losartan in two off-
target risk markers, namely albuminuria and serum potassium is determined in individual patients. 
The relationship of different response patterns in these off-target risk markers with long-term 
renoprotection is also reported in this chapter. The chapters in this thesis in combination with 
existing literature demonstrate that ARBs, registered as antihypertensive drug, influences multiple 
renal risk markers and most of them influence renal outcome, either positively or negatively. This 
implies that calculating the integrated effect of an ARB on all these risk markers will likely result 
in a better prediction of the true renoprotective effect of an ARB on clinical meaningful endpoints, 
such as dialysis or renal transplantation. In chapter 5 we constructed and validated a multiple 
parameter risk response score to determine the integrated effect of a drug, in our case an ARB, 
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Background: Optimal renal and cardiovascular risk management in diabetic patients includes 
optimal maintenance of blood pressure, glucose and lipid control. Although optimal control of these 
risk factors or “risk/biomarkers” has proven efficacy, it often is difficult to achieve. Consequently, 
the risk for renal and cardiovascular complications remains devastatingly high. Many risk/
biomarkers have been discovered that accurately predict long-term renal and cardiovascular 
outcome. However, the aim of measuring risk/biomarkers may not be only to determine an 
individual’s risk, but also to use the risk/biomarker level to guide therapy and thereby improve 
long-term clinical outcome. 
Content: This review describes the effects of various drugs on novel risk/biomarkers and the 
relationship between (drug induced) short-term changes in risk/biomarkers and long-term renal and 
cardiovascular outcome in patients with diabetes. 
Summary: In post-hoc analyses of large trials, the short-term reductions in albuminuria, 
transforming growth factor-β and N-terminal pro-B-type natriuretic peptide (NT-proBNP) induced 
by inhibitors of the renin-angiotensin-aldosterone system were associated with a decreased 
likelihood of renal and cardiovascular outcomes in the long-term. However, the few studies 
that systematically investigated the utility of prospectively targeting novel risk/biomarkers such 
as hemoglobin or NT-proBNP failed to demonstrate long-term cardiovascular protection. The 
latter examples suggest that although a risk/biomarker may have superior prognostic ability, 
therapeutically changing such a risk/biomarker does not necessarily improve long-term outcome. 
Thus, to establish the clinical utility of other novel risk/biomarkers, clinical trials need to 
prospectively examine the effects of therapeutically-induced changes in single or multiple risk/
biomarkers on long-term risk management of patients with diabetes. 
Drug induced changes in risk/biomarkers and




Patients with diabetes mellitus are prone to develop a broad range of complications. The most 
common of these are renal and cardiovascular (CV) complications that are associated with a large 
burden of social dysfunction and with high risk of premature death. 
Several modifiable risk factors are associated with poor renal and CV outcome, including 
blood pressure, plasma glucose and lipid concentrations, smoking, and body weight. This review 
will distinguish between modifiable risk factors and biomarkers in the following way: A modifiable 
risk factor or risk marker (hereinafter called risk factor or risk marker) is a biological characteristic 
that is causally correlated to a clinical endpoint, and its intervention-induced change should predict 
outcome; the risk factor differs from a biomarker in that the latter is a biological characteristic 
indicating a normal biologic process, a pathogenic process or an effect of treatment on such a 
process.(1) Biomarkers are often used as surrogate endpoints in clinical studies. In such studies the 
biomarker is used to substitute for a clinical endpoint. It is hoped that the biomarker will directly 
reflect the disease process under investigation but could be indirectly related. It is therefore possible 
that changes in the biomarker will not directly correlate to the treatment or desired outcome.
Although all risk markers can be considered biomarkers, it is likely that only a subset of 
biomarkers will achieve risk marker status. Blood pressure is a clear example of a risk marker 
because it is causally related to CV disease and the reduction in blood pressure induced by 
an antihypertensive agent is related to the degree of CV risk reduction.(2) Angiotensin is an 
example of a biomarker, where high angiotensin concentrations are a reflection of renal disease 
and where therapy induced change in Angiotensin concentrations may reflect the efficacy of the 
therapy, without a direct causal relationship between Angiotensin and renal disease. There are also 
examples where the boundaries between risk marker and biomarker are overlapping. For example, 
albuminuria is a reflection of renal damage. As such it is a biomarker of renal disease state. On 
the other hand, albuminuria is also believed to be a causal factor in progressive renal function 
loss. Treatments that lower albuminuria lower the risk for renal and cardiovascular disease. In this 
respect albuminuria is also a risk factor/marker. Thus the differentiation between risk marker and 
biomarker is not always as well-defined as one may infer. Throughout this review we will use the 
term risk/biomarker without taking away the potential differential relation.
In clinical practice there are several risk/biomarkers that can be used as a target to improve 
renal and CV protection. However, it appears that optimal control of these risk/biomarkers is 
difficult to achieve. This is illustrated by the multi-factorial intervention trial Steno-2. In this study 
only a small proportion of patients achieved optimal risk/biomarker control despite intensive renal 
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and CV protective therapy.(3) Consequently, a substantial proportion of patients remain at a high 
renal and CV risk.(4) 
A host of articles on novel risk/biomarkers is currently being published in medical literature. 
Many of these publications intend to show that the novel risk/biomarkers at hand has the ability to 
identify more accurately patients with diabetes at risk for development of renal and CV diseases.
(5, 6) Nevertheless, although this may be true, one has to realize that the goal of measuring risk/
biomarkers is not only to determine an individual’s risk but also to use the risk assessment to guide 
appropriate therapy and thereby to improve long-term clinical outcome. It is therefore important to 
obtain insight into the effects of therapeutic approaches on short-term changes (observed within the 
first months after initiation of therapy) in these new risk/biomarkers, and to delineate whether these 
short-term drug-induced risk/biomarker changes are associated with long-term reductions in risk 
for renal and CV outcomes in ensuing years. Such information will allow the doctor and patient to 
use the risk/biomarker as a risk estimator as well as use it as an estimate for therapy success. This 
review will discuss (1) the impact of treatment on novel renal and CV risk/biomarkers (excluding 
traditional risk factors such as blood pressure, glucose, lipids, body weight, and smoking), and 
(2) delineate whether short-term treatment-induced changes in single or a panel of multiple risk/
biomarkers predict changes in risk for long-term renal and CV outcomes.
Targeting single risk/biomarkers
Albuminuria
Albuminuria, a marker of generalized vascular dysfunction, is one of the most frequently evaluated 
risk/biomarkers in patients with diabetes. Large observational studies in patients with diabetes have 
shown that it is a valuable marker in predicting the risk for renal and CV disease.(7-9) In addition, 
various drugs are known to lower albuminuria. Well known are the albuminuria-lowering effects 
of renin-angiotensin-aldosterone system (RAAS) inhibitors. These agents lower albuminuria by 
approximately 40%.(10) The (short-term) reduction in albuminuria achieved with RAAS inhibitors 
may be a critical step in achieving long-term protection against renal events (defined throughout 
this review as the need for chronic dialysis or renal transplantation) and CV events. Post-hoc 
analyses from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan 
Study (RENAAL) trial in patients with diabetes illustrated that each 50% reduction in albuminuria 
induced by treatment with an angiotensin receptor blocker (ARB) during the first months of therapy 
was associated with 45% and 18% risk reduction for renal and CV events during the ensuing 3.4 
years follow-up respectively (Table 1 and Figure 1).(11, 12) Similar results were observed in the 
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Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation 
(ADVANCE) trial. The ADVANCE trial illustrated that each halving of albuminuria during follow-
up, achieved with combination therapy consisting of an Angiotensin Converting Enzyme inhibitor 
(ACEi) and diuretic, resulted in 20% risk reduction for CV events.(7)
A relevant scientific question is whether the short-term albuminuria lowering effects of 
RAAS inhibitors, registered as antihypertensive drugs, are mediated through their effect on blood 
pressure only, or whether they are the result of a combination of effects (including the lowering 
of blood pressure). Indeed, RAAS inhibitors have multiple other effects such as lowering of 
albuminuria. If albuminuria reduction confers renal and CV protection independent of changes in 
blood pressure, or other risk/biomarkers, such evidence would support the validity of albuminuria 
as an independent target for renal and CV protective therapy. The renoprotective effects of RAAS 
inhibitors beyond blood pressure control were initially discovered in non-diabetic patients. The 
Ramipril Efficacy in Nephropathy (REIN) trial showed that ramipril lowered the risk of End Stage 
Renal Disease as compared to conventional antihypertensive therapy at similar level of blood 
pressure control.(13) These results extended to the type 2 diabetic population. The Irbesartan 
Diabetic Nephropathy Trial compared the effects of an ARB (irbesartan), Calcium Channel 
Blocker (amlodipine), and placebo in patients with diabetic nephropathy.(14) The rationale to 
include a calcium channel blocker arm in this trial was to determine blood pressure independent 
renoprotective effects of the ARB.(15) The trial showed that irbesartan significantly lowered the 
risk for renal events compared to amlodipine despite similar blood pressure control. A post-hoc 
analysis of this trial further illustrated that irbesartan’s superior renoprotective effect could be in 
large part attributed to its effect on proteinuria reduction.(16) However, when the authors compared 
the renoprotective effects of irbesartan versus amlodipine at similar degrees of blood pressure 
and proteinuria reduction, irbesartan still provided better renoprotection. This finding indicated 
that the pharmacological effects of irbesartan could not be fully explained by its effects on blood 
pressure and proteinuria alone and implied that irbesartan’s effect on other, yet unidentified, risk/
biomarkers, was involved in its long-term renoprotective effect. The results of this study argued for 
the simultaneous measurement of short-term changes in multiple risk/biomarkers in explaining the 
overall pharmacological effects of an agent on long-term hard renal and CV outcomes.
Further indirect evidence supporting the validity of albuminuria as an independent target 
for renal and CV protective therapy comes from a detailed analysis by Eijkelkamp et.al.(17) In this 
analysis of the RENAAL trial the blood pressure response to an ARB (losartan) was dissociated 
from the albuminuria response. The study showed that long-term renoprotection was related to the 
Chapter 2
22
degree of albuminuria lowering and to a lesser extent to the degree of blood pressure lowering. 
Thus, RAAS inhibitors play a unique role in renal and CV therapy because of the protection they 
afford which is mediated, at least in part, through their effect on albuminuria. 
Although of interest, these post-hoc analyses can only be interpreted as hypothesis 
generating. To evaluate monitoring and targeting albuminuria as an effective treatment strategy, 
one group of patients should be assigned to frequent measurement and adjustment of medication 
if targets are not met, while the other group receives standard care. Such a design would isolate 
the role of targeting albuminuria by focusing on the additive effect of monitoring albuminuria as 
compared with standard therapy, and provide a better approach to establish the clinical relevance 
of targeting albuminuria for renal and CV protection. Such a trial has not yet been conducted, 
although Hou et.al. came very close with the design and results of the Renoprotection of Optimal 
Antiproteinuric Doses (ROAD) trial, conducted in non-diabetic patients. Hou et al. aimed to 
specifically target albuminuria using dosages of ACEis or ARBs well above the dosage that is 
conventionally used for blood pressure reduction. It is known that such high dosages of ACEis or 
ARBs confer additional antiproteinuric effects beyond their blood pressure lowering effect.(18, 
19) Hou et.al. reported that targeting albuminuria with optimal antiproteinuric dosages of ACEis or 
ARBs resulted in much better renal protection than conventional antihypertensive therapy despite 
similar blood pressure control.(20) Although these results are promising, further studies are needed 
to resolve the issue whether specific lowering of albuminuria results in renal and CV protection. 
Since RAAS inhibition forms the mainstay therapy for renal and CV protective therapy, 
the albuminuria lowering effects of novel agents are now tested on top of RAAS inhibition. 
Thiazolidinediones, oral glucose lowering drugs, act through stimulation of the peroxisome 
proliferator activated receptor γ. These drugs have been shown to significantly lower albuminuria 
in patients with diabetes.(21, 22) Another target has been the Vitamin D receptor. Studies have 
indicated that Vitamin D Receptor Activators (VDRA) exert albuminuria lowering effects through 
suppression of the RAAS and anti-inflammatory effects.(23, 24) Apart from VDRA therapy, 
HMG-CoA reductase inhibitors (statins) also lowered albuminuria, but this seems to be a specific 
drug effect since not all statins uniformly lowered albuminuria.(25, 26) Another target to lower 
albuminuria has been blocking the endothelin type A receptor in the endothelin system, which 
seems to play a role in the pathogenesis of albuminuria. Several studies have shown that blocking 
the endothelin type A receptor significantly reduced albuminuria up to 40% in patients with type 
2 diabetes and nephropathy beyond optimal RAAS blockade.(27, 28) Although effective, the side 
effects of endothelin antagonists, in particularly fluid overload, have been a cause of concern and 
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may blunt the CV protective effects of albuminuria lowering. To date, no hard endpoint trial has 
been completed with either VDRAs, statins, or endothelin antagonists. Thus, whether short-term 
reductions in albuminuria during either VDRA, statin, or endothelin antagonist therapy relate to 
reductions in the risk for hard renal and CV events remain unknown.
The utility of (changes in) albuminuria as a risk/biomarker for renal and CV disease have 
been debated extensively. Critics have focused on at least three issues: variability of the albuminuria 
within an individual, absence of albuminuria in patients with renal or CV function loss, and finally 
large trials that deny the importance of albuminuria as a predictor or a target for treatment. First, 
studies have shown that the variability in albuminuria is large and as such albuminuria would not 
be a good risk/biomarker. Indeed, large random day-to-day fluctuations in any risk/biomarker 
hamper the accuracy and precision to predict changes in renal and CV risk. When examined at the 
individual level, studies have shown that albuminuria varies from day-to-day.(29) However, when 
examined at the group level, the variability in albuminuria was equal to the variability in other risk/
biomarkers.(27) Secondly, studies have shown that patients without albuminira can have progressive 
renal function loss. This is no surprise, since albuminuria is just like other risk/biomarkers, one 
of the many contributors to renal and CV disease. Obviously, other factors likely play a role in 
disease progression.(30) Importantly, the available evidence clearly has shown that increased 
levels of urine albumin when present are an excellent predictor of later renal and cardiovascular 
problems in patients with and without diabetes.(31) Thirdly, the Ongoing Telmisartan Alone and 
in combination with Ramipril Global Endpoint (ONTARGET) trial showed that despite additional 
albuminuria reduction, combination therapy of ACEi and ARB did not confer CV protection and 
even increased the risk of renal disease.(32, 33) This led to lively discussion about the validity of 
albuminuria as a risk/biomarker of renal disease and recommendations to dismiss albuminuria as a 
surrogate endpoint for renal and cardiovascular protection. Intriguingly, the discussion focused on 
albuminuria, although blood pressure was also further reduced in the combination arm. Since the 
combination arm showed no further protection in long-term outcomes, it would have been equally 
valid to consider dismissing blood pressure as a valid risk/biomarker! With regard to albuminuria in 
the ONTARGET trial, a recent analysis provided ample evidence that both baseline albuminuria as 
well as changes in albuminuria during the first years predicted the risk for renal and CV events in 
the following years.(34) This was in contrast with the earlier ONTARGET renal report which gave 
the impression that albuminuria was not a valid renal risk predictor. Thus, the recent ONTARGET 
analysis further substantiates numerous previous studies demonstrating that in individual patients 
changes in albuminuria are an excellent predictor for changes in future renal and CV risk.
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Figure 1: Associations between the proportional change in different renal and cardiovascular (CV) 
risk/biomarkers and the risk for CV outcomes. The data show the relationship between the short-
term change in respectively albuminuria (RENAAL) (11), proBNP (Val-HeFT) (57) and hs-CRP 
(JUPITER)(56) and CV outcome. The JUPITER trial reported CV hazard ratio for rosuvastatin 
assigned patients with less than 50% and more than 50% reduction in hs-CRP compared to placebo 
which was used as reference. For illustrative purposes, it was assumed that a reduction in hs-CRP 
of less than 50% resulted in a mean reduction of 30% whilst a reduction of more than 50% resulted 
in a mean reduction of 80%.
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Table 1: Overview of studies in patients with diabetes determining the association between drug 
induced changes in risk/biomarkers with long-term renal or CV risk change.a
Risk/biomarker      Trial                          Intervention                    Risk/biomarker change                     Change of  long-term renal or CV risk 
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C o m p a r e d  t o  p l a c e b o , 
albuminuria was reduced with 
32% in albuminuria after 6 
months.
C o m p a r e d  t o  p l a c e b o , 
albuminuria levels were 30% 
lower in irbesartan treated 
subjects after 12 months.
Cap topr i l  caused  a  25% 
reduction in TGF- β compared 
to placebo during the initial 6 
months.
Hemoglobin levels increased 
from 104 to 106 g/L and from 
104 to 125 g/L in respectively 
placebo and darbepoetin-α 
treated subjects. 
3573  (46%) par t ic ipants 
assigned to rosuvastatin had 
a reduction in hs-CRP more 
than 50%. 
Compared to placebo, NT-
proBNP levels were 6.5 ng/
L lower in intensive treatment 
arm after 2 years.
Compared to conventional 
intervention, intensive treatment 
reduced LDL cholesterol 
0.3 mmol/L, HbA1c 1.0%, 
albuminuria  32 mg/24hr, 
and systolic blood pressure 4 
mmHg.
Each halving of albuminuria during 
the first 6 months was associated with 
a reduction in the risk of renal and CV 
disease of respectively 45% and 18% 
during 3.4 years follow-up.
Each halving of proteinuria during the 
first 12 months was associated with a 
risk reduction in end stage renal disease 
of 56% during 2.9 years follow-up.
An inverse correlation was found 
between the change in TGF-β and the 
percentage change in eGFR over the 
ensuing 2 years (r=-0.45; P=0.008).
Darbepoetin-α increased hemoglobin 
levels but it did not reduce the risk of 
renal or CV events. 
A post-hoc analysis showed that despite 
receiving high dosages of Darbepoetin-α, 
patients with a poor response during the 
first 4 weeks had a higher risk of CV 
outcomes.
Compared to placebo, participants 
assigned to rosuvastatin who achieved 
a CRP reduction more than 50% had a 
54% CV risk reduction.
A 10 ng/L reduction in NT-proBNP 
during the first 2 years was associated 
with a significant 1% CV risk reduction 
during a median follow-up of 7.8 years.
Intensive treatment attenuated the risk 
of nephropathy (risk reduction 44%) 
retinopathy (risk reduction 55%), CV 
events (risk reduction 59%) and death 






aAll listed studies enrolled patients with diabetes except the JUPITER trial which included apparently healthy individuals with 
high CRP. 
Abbreviations: BNP Brain Natriuretic Peptide; CRP, C-reactive Protein; JUPITER, Justification for the Use of Statins in Primary 
Prevention: An Intervention Trial Evaluating Rosuvastatin, IDNT, Irbesartan in Diabetic Nephropathy; RENAAL, Reduction 





Transforming Growth Factor-β (TGF-β) has a key role in the processes that lead to an increase in 
matrix components, infiltration of macrophages in renal tissue, and loss of nephrons eventually 
leading to diabetic nephropathy. Therefore, it is not surprising that presence of TGF-β has been 
shown to predict the onset of End Stage Renal Disease. 
TGF-β is an important transducer of the pathogenetic effects of Angiotensin II and its levels 
are controlled by the RAAS. This has led to studies investigating whether the effects of RAAS-
inhibitors on TGF-β could account for the renoprotective effects of RAAS-inhibitors beyond blood 
pressure and albuminuria lowering. To this end, the changes in serum TGF-β levels at 6 months 
induced by the ACEi captopril, were measured and correlated to the 2-year rate of renal function 
decline in patients with type 1 diabetes.(35) Captopril caused a significant decline in TGF-β levels 
compared to placebo. The degree of TGF-β reduction coincided with the degree of glomerular 
filtration rate (GFR) preservation during the ensuing 2 years follow-up (table 1). Thus, if TGF-β 
declined at 6 months the rate of renal function decline during the subsequent 2 years follow-up was 
smaller. An important question was whether the changes in TGF-β were independent of changes in 
albuminuria. Another study provided more insight into the independent effects of RAAS-inhibition 
on TGF-β levels. Agarwal et al. found that 4-weeks treatment with the combination of an ACEi 
and an ARB significantly attenuated TGF-β levels. Interestingly, the reductions in TGF-β levels 
occurred independent of changes in 24-hr urinary protein excretion or blood pressure.(36) These 
data suggest that the effect of RAAS-inhibition on TGF-β may in part explain its renal protective 
effect. However, the definitive answer on whether TGF-β suppression is independently associated 
with renoprotection should come from randomized controlled trials. 
Hemoglobin
Anemia is a common finding in patients with diabetes and it has potential to negatively affect well-
being and social functioning. Clear evidence is available that anemia is an independent potent risk 
factor for CV disease.(37-39) The role of anemia as CV risk factor appears to extend to progression 
of chronic kidney disease. In patients with type 2 diabetes, anemia has been documented to be an 
independent risk factor for doubling of serum creatinine (50% reduction in Glomerular Filtration 
Rate) or End Stage Renal Disease.(9) 
Various drugs affect hemoglobin levels. First, ARBs are known to lower hemoglobin levels 
(an unwanted side effect). The reductions in hemoglobin during ARB therapy appear not to affect 
the overall efficacy of ARBs on the progression of renal disease. Toto et.al. demonstrated that the 
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long-term renoprotective effects of the ARB losartan in individuals with diabetes and nephropathy 
persisted in the presence of a significant reduction in hemoglobin.(40) These data indicated that a 
reduction in hemoglobin during the initial months after start of ARB therapy did not necessarily 
imply a dose reduction or discontinuation of treatment altogether.
Erythropoiesis-stimulating-agents (ESA) are a class of agents that are intended to target 
hemoglobin levels and bring them towards normalcy. Despite the absence of high quality outcome 
data, ESA therapy has been frequently used based on the expectation that correction of anemia 
improves renal and CV outcome. Data from the Trial to Reduce Cardiovascular Events with 
Aranesp Therapy (TREAT), however, created a dilemma: ESA-therapy increased hemoglobin 
levels after just 3 months therapy but did not confer long-term renal or CV protection.(41) These 
results were highly remarkable because theoretically increasing oxygen delivery and improving CV 
hemodynamics should improve vascular outcomes.(42) Although a lot of attention has centered on 
the hemoglobin targets used in these trials, another explanation could be that high ESA exposure 
itself might account for the detrimental effects. Indeed, a post-hoc analysis of the TREAT trial 
demonstrated that patients with a poor hematopoietic response to ESA therapy (those within the 
lowest quartile of the 4-weeks hemoglobin change) were more likely to experience a CV event 
or die as compared to responsive patients (Table 1)(43). These data underscore the importance of 
considering individualized therapeutic responsiveness and limiting dose escalation in those not 
attaining targeted hemoglobin goals. Further studies, such as the Clinical Evaluation of the DOSe 
of Erythropoietins (CEDOSE) trial testing the effects of fixed dose ESA combinations, should 
provide additional evidence whether the ESA dose itself or the targeted hemoglobin level mediates 
the increased risk of adverse renal and CV outcomes.(44) Nevertheless, the lack of renal and CV 
protective effect despite increasing hemoglobin levels in the TREAT trial indicate that hemoglobin 
is a poor risk/biomarker to follow the response of ESA therapy.  
C-reactive protein
In recent years, it has been postulated that chronic low-grade tissue inflammation may play a critical 
role in initiation and progression of atherosclerosis and diabetic renal and CV injury. Several 
studies have demonstrated that measurement of low-grade inflammatory risk/biomarkers, among 
them high sensitivity C-reactive protein (hs-CRP), improves CV risk stratification, particularly in 
those already at intermediate or high CV risk.(45-48).The predictive ability of hs-CRP goes beyond 
CV risk prediction. Laaksonen and Brantsma have provided evidence that the presence of elevated 
concentrations of hs-CRP in apparently healthy individuals is associated with increased risk for de 
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novo type 2 diabetes.(49, 50)
Statin therapy has greatest effects in the presence of inflammation. Several studies show 
that statin therapy reduces hs-CRP.(51, 52) In trials of patients with coronary disease and acute 
coronary syndrome, the benefits of statin therapy relate at least in part to their effect on hs-
CRP reduction.(53, 54) The recent Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin trial (JUPITER) trial was designed to study the effect 
of rosuvastatin in people with normal Low Density Lipoprotein-levels (LDL) but increased hs-
CRP concentrations. The trial showed that rosuvastatin lowered LDL-cholesterol and hs-CRP in 
the short-term and markedly lowered the long-term risk for CV events.(55) In this trial rosuvastatin 
both lowered LDL-cholesterol and hs-CRP. Thus whether the reductions in hs-CRP or LDL or 
combined (or another undiscovered risk/biomarker) were the driving parameter for CV protection 
could not be established. A post-hoc analysis recently provided further insight into this topic. This 
analysis demonstrated that in patients assigned to rosuvastatin who achieved LDL-cholesterol of 
less than 1.8 mmol/L and hs-CRP of less than 2 mg/L at 1 year had substantially lower risk for CV 
events compared to those who achieved neither target or only LDL-cholesterol less than 1.8 mmol/
L (Table 1 and Figure 1).(56) The correlation between the achieved LDL-cholesterol and hs-CRP 
concentrations was small indicating that only a small part of the achieved hs-CRP concentration 
could be explained by the achieved LDL-cholesterol. These data suggest that the extent to which 
statins lower hs-CRP and LDL-cholesterol in the short term determines the degree of long-term CV 
protection. 
As was the case for the post-hoc analyses of albuminuria trials described above, the 
JUPITER trial did not provide direct evidence that monitoring of hs-CRP to guide the intensity of 
statin therapy resulted in improved CV outcomes. An alternative JUPITER design in which one 
group of patients is assigned to intensive hs-CRP targeting while the control group receives usual 
care would have provided direct evidence of the value of a hs-CRP targeted intervention approach. 
Until such data become available, the efficacy of improving health outcomes using hs-CRP as a 
target is not proven. 
NT-ProBNP
Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a risk/biomarker of the cardiac 
response to volume overload. In the setting of increased volume expansion, pre-proBNP is released 
and subsequently converted into active BNP and inactive NT-proBNP. Studies in patients with 
diabetes and diabetic nephropathy have shown that NT-proBNP is an important prognostic marker 
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for CV events and all cause mortality. 
ACEi and ARBs reduce plasma concentrations of NT-proBNP in post-myocardial infarction 
and congestive heart failure patients. Anand et.al demonstrated that the ARB valsartan caused a 
sustained reduction in brain natriuretic peptide (BNP) within 4 months of therapy. Individuals 
in whom BNP concentrations were attenuated during the first 4 months had markedly lower risk 
for long-term CV events than those in whom BNP rose during the first months of therapy (Figure 
1).(57) The Steno-2 trial in patients with type 2 diabetes showed that intensive targeting of multiple 
CV risk factors reduced NT-proBNP during follow-up compared to conventional therapy.(58) 
Interestingly, the magnitude of NT-proBNP reduction during the first 2 years of treatment was 
associated with the reduction in CV risk during the subsequent 6 years of follow-up (Table 1). 
These results suggest that attenuating NT-proBNP levels in the short-term improves long-
term health outcomes. However, as mentioned above, such post-hoc analyses do not provide direct 
evidence that a NT-proBNP targeted approach confers long-term renal and/or CV protection. A 
couple of RCTs have been conducted to test the hypothesis that a NT-proBNP targeted approach 
improves long-term CV outcomes. The earlier trials showed promising effects in terms of CV 
outcomes. However these trials were performed in small populations and had limited duration of 
follow-up.(59, 60) Pfisterer et. al. recently investigated a NT-proBNP guided strategy in a larger 
cohort of 499 heart failure patients of whom approximately one third had diabetes.(61) The trial 
failed to achieve significant differences in NT-proBNP concentrations between the two treatment 
groups, although NT-proBNP concentrations were numerically lower in the targeted group. After 18 
months, no CV benefit was observed in patients assigned to NT-proBNP targeted therapy compared 
to those receiving conventional symptom-guided therapy. Thus, the value of specific targeting of 
NT-proBNP on top of symptom guided therapy seems limited, at least in this population of patients 
with heart failure, despite the unquestionable diagnostic and prognostic significance of NT-proBNP. 
Whether a NT-proBNP targeted approach confers renal or CV protection in other populations 
warrants further research.
Targeting multiple risk/biomarkers 
Since the etiology of diabetes is multi-factorial, it has been suggested that a multi-factorial approach 
targeting the various pathways involved in the pathogenesis of diabetes simultaneously would 
lead to more salutary long-term outcomes. One of the few studies that evaluated systematically 
the long-term effects of a multi-factorial treatment strategy in type 2 diabetes is the Steno-2 trial.
(3) The intensive multi-factorial intervention consisted of pharmacological agents targeting blood 
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pressure, HbA1c, lipid concentrations and of behavioral modifications including smoking cessation 
and diet changes. After 4 years follow-up, multi-factorial intervention slowed the progression of 
nephropathy and retinopathy. In addition, the long-term follow-up data of this study demonstrated 
that patients assigned to intensive multi-factorial intervention had a considerable significantly lower 
risk for CV events and mortality, highlighting the importance of a multi-factorial treatment regimen 
(table 1).(62)
A new class of oral glucose lowering agents is currently under development targeting 
multiple risk/biomarkers. These drugs are designed as selective inhibitors of the sodium-glucose 
co-transporter (SGLT2). The SGLT2 receptor mediates glucose (and sodium) reabsorption in the 
proximal tubule of the kidney.(63) Randomized controlled trials have shown that blockade of the 
SGLT2 receptor increases urinary glucose excretion and lowers HbA1c.(64) Intriguingly, these 
drugs appear to have favorable effects on other renal and CV risk/biomarker as well, including 
blood pressure and body weight reduction.(64) Thus, multiple renal and CV risk/biomarkers are 
targeted with a single drug. Supposedly, these multiple favorable effects result in substantial renal 
and CV protection. A couple of trials are currently underway testing the efficacy and safety of 
SGLT2 inhibitors on renal and CV endpoints. The results of these trials are eagerly awaited.
Other novel risk/biomarkers
Besides the risk/biomarkers discussed above, the effects of different pharmacological agents on 
other single risk/biomarkers predicting CV and renal disease have been tested. Several studies have 
shown that RAAS inhibiting therapy can modify risk/biomarkers reflecting endothelial and tubular 
damage and inflammation.(65-71) Furthermore, metformin has been reported to lower inflammation 
biomarkers.(72)  However, to the best of our knowledge, all these studies were performed in small 
populations with only limited duration of follow-up. Therefore, the impact of short-term treatment 
induced changes in these risk/biomarkers on long-term hard renal and CV outcomes cannot be 
ascertained. Further studies are clearly warranted to test whether therapeutic interventions aimed at 
targeting these novel risk/biomarkers afford long-term protection. If so, the clinical utility of these 
novel risk/biomarkers in the management of diabetic renal and CV complications will increase.
Conclusion
Over the last two decades, a vast number of risk/biomarkers predicting renal and CV complications 
have been discovered. However, few studies have systematically tested whether short-term 
treatment-induced changes in these risk/biomarkers relate to long-term protection. Moreover, 
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whether a targeted approach, directed at changing a panel of multiple novel risk/biomarkers, will 
improve long-term renal and CV outcome remains an unsolved question. The examples with 
targeting single novel risk/biomarkers, such as hemoglobin and NT-proBNP, teach us that although 
a risk/biomarker may have superior prognostic ability, such ability does not automatically imply 
that specific targeting of and changing such a risk/biomarker will improve long-term outcome. 
Thus, to establish the clinical utility of novel risk/biomarkers in guiding treatment intensity, specific 
protocols need to be developed and employed to demonstrate that targeting single (or multiple) 
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Background: Emerging data show that increased serum uric acid (SUA) concentration is an 
independent risk factor for End-Stage-Renal-Disease (ESRD). Treatment with the antihypertensive 
drug losartan lowers SUA. Whether reductions in SUA during losartan therapy are associated with 
renoprotection is unclear. We therefore tested this hypothesis. 
Methods: In a post-hoc analysis of 1342 patients with type 2 diabetes and nephropathy 
participating in the RENAAL trial, we determined the relationship between month 6 change in SUA 
and renal endpoints, defined as a doubling of serum creatinine or ESRD.
Results: Baseline SUA was 6.7 mg/dl in placebo and losartan treated subjects. During the first 
6 months, losartan lowered SUA by -0.16 mg/dl (95%CI -0.30 to -0.01; p=0.031) as compared 
with placebo. The risk of renal events was decreased by 6% (95%CI 10% to 3%) per 0.5 mg/dl 
decrement in SUA during the first 6 months. This effect was independent of other risk markers, 
including eGFR and albuminuria. Adjustment of the overall treatment effects for SUA attenuated 
losartan’s renoprotective effect from 22% (95%CI 6 to 35) to 17% (95%CI 1 to 31), suggesting that 
about one-fifth of losartan’s renoprotective effect could be attributed to its effect on SUA.
Conclusion: Losartan lowers SUA levels compared to placebo treatment in patients with type 2 
diabetes and nephropathy. The degree of reduction in SUA is subsequently associated with the 
degree in long-term renal risk reduction and explains part of losartan’s renoprotective effect. These 
findings support the view that SUA may be a modifiable risk factor for renal disease.




Over the past decades, serum uric acid has emerged as a cardiovascular risk marker. Increased 
serum uric acid has been shown to predict the risk of hypertension, diabetes, and cardiovascular 
disease.(1-3) More recent data also point to serum uric acid as a risk marker for progression of 
chronic kidney disease.(4, 5)
These observations raise the question as to whether interventions that lower uric acid could 
confer cardiovascular or renal protection. In this respect, the angiotensin receptor blocker losartan 
is of potential interest. The drug has been clearly demonstrated to be renoprotective in patients 
with diabetic nephropathy, this effect largely attributed to its effects on blood pressure and/or 
proteinuria/albuminuria.(6) However, it is unclear whether other off-target effects of the drug could 
contribute to the ultimate improvement in renal outcome with this agent. Importantly, previous 
studies have shown that losartan lowers serum uric acid. This hypouricemic effect does not occur 
with other ARBs,(7) and appears to be largely mediated through reductions in the level of human 
urate transporter 1 (URAT1) and decreased net urate reabsorption in the proximal tubule.(8-10)
With respect to cardiovascular endpoints, a sub-analysis from The Losartan Intervention 
For Endpoint reduction in hypertension (LIFE) trial showed that the superior effect of losartan 
could be partly explained by its effect on serum uric acid.(11) Whether the same holds true for the 
long term renoprotective effect of losartan is unknown but is worth investigating in the context 
of the increased body of evidence linking uric acid to the progression of chronic kidney disease.
(12) The aim of the present study, therefore, was to assess whether losartan induced changes in 
uric acid during initial months of therapy are associated with decreased (long-term) risk of readily 
measurable renal outcomes in patients with type 2 diabetes and nephropathy.
Methods
Study Design
The Reduction of Endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II 
Antagonist Losartan (RENAAL) trial was a multinational, randomized, double-blind trial that 
compared the effects of losartan versus placebo in addition to conventional antihypertensive 
medication in patients with type 2 diabetes and nephropathy. Patients had serum creatinine levels 
between 1.3 and 3.0 mg/dl (1.5 to 3.0 mg/dl for males more than 60 kg). The study was performed 
in 250 centers in 28 countries and involved 1513 patients. The study design, the inclusion/
exclusion criteria, and the treatment protocol have been reported previously.(13) In short, after a 
6-week screening phase, patients were randomized to either losartan 100 mg or placebo. Additional 
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antihypertensive medications (calcium channel blockers, β-blockers, centrally acting agents, 
and diuretics, excluding angiotensin-converting enzyme inhibitors or other angiotensin receptor 
antagonists) were permitted in order to achieve the blood pressure goal of < 140/90 mmHg (systolic/
diastolic). All patients signed informed consent before enrollment, and the local Institutional 
Review Board of each participating center approved the study. The mean duration of follow-up was 
3.4 years. The RENAAL trial is registered with Clinical trials.gov, identifier: NCT 00308347.
Measures and outcomes
In this study, we performed a post-hoc analysis of all subjects with uric acid measurements 
included in the RENAAL trial. Blood pressure, serum uric acid, serum creatinine and albuminuria 
were measured at a 3 monthly basis and HbA1c was measured every six months for the duration 
of the study. Albuminuria was assessed as the ratio of albumin to creatinine concentrations from a 
first-morning-void urine sample. The MDRD formula was used to estimate GFR (eGFR).(14) We 
assessed the relationship between change in serum uric acid level at month 6 and renal outcomes. 
The change from baseline to month 6 was chosen since this is the earliest time point at which most 
variables of interest were available, the treatment effects were considered to be fully manifest, 
and relatively few renal events occurred before month 6.(15) Changes in serum uric acid, blood 
pressure, albuminuria and HbA1c were calculated as baseline minus month 6. 
The primary renal outcome was defined as a composite of a confirmed doubling of serum 
creatinine (DSCR) or End Stage Renal Disease (ESRD). The latter was defined as the need for 
chronic dialysis or renal transplantation. All endpoints were adjudicated by a blinded endpoint 
committee using rigorous guideline definitions.
Statistical Analysis
Patients with serum uric acid measurements at baseline and month 6 were included in the present 
analysis. Mean serum uric acid at each visit during follow-up was calculated in both the losartan 
and placebo group. Patient characteristics were summarized according to tertiles of month 6 
changes in serum uric acid. To identify parameters associated with a change in serum uric acid 
at month 6, a multivariate logistic regression model was used. Baseline characteristics as well as 
month 6 changes in systolic and diastolic blood pressure, HbA1c, log transformed albuminuria, 
and eGFR were included in the multivariate model. A backward selection procedure was used for 
selection of covariates for the final model (α=0.1).
The proportion of patients without renal events was estimated using the Kaplan-Meier 
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procedure. Multivariate Cox regression analyses were performed to determine whether changes 
in serum uric acid were independently associated with renal outcomes. Changes in serum uric 
acid were included in the Cox model as a continuous variable. All analyses were adjusted for risk 
markers that showed a statistically significant association with month 6 change in uric acid. These 
included: age, gender, treatment assignment (losartan or placebo), eGFR, systolic blood pressure, 
log transformed albuminuria, serum albumin, ACEi or ARB use at baseline, and changes in log 
transformed albuminuria and eGFR. Finally, the contribution of therapy induced changes in serum 
uric acid on losartan’s renoprotective effect was assessed by time-varying Cox regression models. 
Relative risk reductions are described in the text as percentage reductions ([1–hazard ratio] ×100). 
Analyses were conducted with SAS (version 9.2; SAS Institute, Cary, NC). A p-value < 0.05 was 
considered to indicate statistical significance.
Results
 A total of 1342 subjects were involved in the present analysis. In the losartan group, the mean 
serum uric acid remained 6.7 mg/dl during the first 6 months of therapy. By contrast, in the 
placebo group, the mean serum uric acid increased from 6.7 mg/dl at baseline to 6.9 mg/dl at 
month 6, resulting in a mean group difference of -0.16 mg/dl (95% CI -0.30 to -0.01; p=0.031) 
(figure 1). The level of serum uric acid in the placebo group continued to increase from month 6 
onwards. Likewise, the serum uric acid level also started to rise at month 6 in the losartan group. 
The “apparent” fall observed at 36 month in the placebo group is likely to be linked to “drop-
out” of patients in the placebo group with high serum uric acid levels. Patients were subsequently 
classified into tertiles according to the change in serum uric acid at month 6 (table 1). Relevant 
baseline characteristics were not different among the tertile groups apart from serum uric acid and 
albuminuria which were higher and respectively lower in patients who had a decrease in serum uric 




Figure 1: Mean uric acid level during follow-up among patients in the losartan and placebo group 
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Table 1: Characteristics of the overall RENAAL population by treatment allocation and by month 6 
change in uric acid






























































































































































Other treatments, n (%)
  ACEi or ARB
  β-blockers
  Calcium channel blockers
  Diuretics
Follow-up characteristics
Change in uric acid, mg/dl
Change in systolic BP, mmHg
Change in diastolic BP, mmHg
Change in UACR, %
*P<0.05, tests for trend among tertiles of month 6 serum uric acid change
Mean (SD) or numbers of patients (%) were provided for normal distributed continuous variables and categorical variables 
respectively. Due to the skewed distribution of the albumin:creatinine ratio, urinary albumin:creatinine ratio is presented as 
median (interquartile range).
To convert the values of serum uric acid to micromoles per liter, multiply by 59.48. To convert the values of serum creatinine to 
micromoles per liter, multiply by 88.4. To convert the values for cholesterol to millimoles per liter, multiply by 0.0259.
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To investigate the parameters associated with a change in serum uric acid at month 6, a 
multivariate linear regression was performed in the overall population. Allocation to losartan 
therapy was independently associated with a larger fall in uric acid at month 6. Furthermore, higher 
baseline serum uric acid, eGFR, and serum albumin as well as a larger reduction in eGFR and a 
smaller reduction in albuminuria were significantly associated with a larger decrease in serum uric 
acid at month 6 (table 2). 
Table 2: Covariates associated with a change in serum uric acid at month 6
Risk markers
Baseline uric acid
Change urinary albumin:creatinine ratio




Baseline ACEi or ARB use
































The natural log transformed value of urinary ACR and change in natural log transformed urinary ACR was used in all regression 
analyses. Covariates which showed a p-value less than 0.1 in the multivariate analysis are presented in the table. Covariates are 
ordered by decreasing significance based on the Χ2 statistics.
Figure 2 shows the proportion of patients free of renal events during follow-up according to the 
change in serum uric acid. A total of 463 renal events occurred during follow-up. Those subjects 
with a decrease in serum uric acid more than 0.5 mg/dl at month 6 had the lowest risk of developing 
renal endpoints (figure 2). Subsequently, hazard ratios were calculated for finer categories of change 
in uric acid. After controlling for baseline and change in other risk factors we observed an almost 
linear relationship between the change in uric acid and renal outcome (figure 3), so that each 0.5 
mg/dl reduction in serum uric acid during the first 6 months was associated with a reduction in the 
risk of DSCR / ESRD of 6% (95%CI 10 to 3; p<0.001). 
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Figure 2: Kaplan–Meier curves for renal outcomes (DSCR or ESRD). The renal event rates in 
subjects with a month 6 reduction in SUA ≥0.5 mg/dL, serum uric acid (SUA) change between and 
0.5 mg/dL, or an SUA increase ≥0.5 mg/dL were, respectively, 9.5, 12.3, and 14.3 events per 100 
patient-years
Figure 3: Hazard ratios for incident renal outcomes (DSCR or ESRD) as function of month 6 
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To investigate how much of losartan’s renoprotective effect could be attributed to its effect 
on serum uric acid, we analyzed the impact of a reduction in serum uric acid over time on losartan’s 
renoprotective effect. When the treatment effect was adjusted for the residual serum uric acid (the 
last measurement prior to the occurrence of the renal endpoint) the treatment effect of losartan on 
the DSCR / ESRD endpoint attenuated from 22% (95%CI 6 to 35) to 17% (95%CI 1 to 30); that is 
about 4% out of 22% (one fifth) of the benefit of losartan could be attributed to its effect on serum 
uric acid. 
Discussion
This study demonstrates that losartan treatment in patients with type 2 diabetes and nephropathy 
lower serum uric acid levels compared with placebo. Whereas serum uric acid increased in the 
placebo group, this effect was attenuated with losartan in the treated group. A significant lower risk 
for renal events was observed per decrement in serum uric acid during the first 6 months, and the 
association remained statistically significant (and unchanged) after adjustment for a broad range of 
known risk factors. The effect of losartan on serum uric acid explained approximately 20% of its 
renoprotective effect.
This is the first study that directly shows that the effect of losartan on serum uric acid is 
associated with renal risk reduction. Thus, the effect on uric acid by losartan appears not only 
relevant for cardiovascular outcomes as reported in the LIFE study,(11) but also for the renal 
outcome. The estimated contribution of serum uric acid to losartan cardiovascular protective 
treatment effects was calculated to be 29% in the LIFE trial. In the present population, the 
contribution of serum uric acid to losartan’s renoprotective effect was estimated to be 22%. 
The mechanisms through which losartan exerts its hypouricemic effect are well described. 
The proximal tubule has been identified as the primary location of uric acid secretion and 
reabsorption. A central role in proximal tubule urate reabsorption has been ascribed to URAT1. 
URAT1 is located in the lumen of proximal tubule cells and reabsorbs uric acid (as urate) in 
exchange for intracellular anorganic anions. Losartan increases urate excretion by inhibition URAT1 
mediated renal tubule urate reabsorption. Early studies in the healthy population demonstrated 
that the peak uricosuric effect was already observed two to four hours after administration.(16, 17) 
The time course of this effect suggests that it is losartan itself rather than its active metabolite that 
blocks URAT1 and causes the reduction in serum uric acid. Theoretically, the distinct uricosuric 
effect of losartan could lead to increases in urinary uric acid concentration which could lead to 
supersaturation of uric acid and in the extreme case precipitate uric acid nephropathy. However, the 
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risk of development of uric acid crystals during losartan therapy is reduced due to the drug’s urinary 
alkalinizing effects. Treatment with losartan raises urinary pH which is attributed to the blockade of 
angiotensin II induced stimulation of bicarbonate reabsorption. This increase in urinary pH offsets 
the formation of uric acid crystals and reduces the risk of acute uric acid nephropathy.(18)
Emerging evidence demonstrate an association between serum uric acid and adverse renal 
outcomes.(12) Whether this relationship is causal is unclear. Indeed, whether serum uric acid is a 
marker of renal function decline or a risk factor for progressive renal function loss remains a matter 
of ongoing debate. In the kidney serum uric acid is filtered, secreted and reabsorbed. As glomerular 
filtration rate (GFR) declines, the fractional excretion of uric acid increases. However, this process 
does not completely counterbalance the fall in GFR. Consequently, serum uric acid levels start to 
rise. It is therefore reasonable to suggest that changes in serum uric acid are a result of renal disease 
and have no direct pathogenic role. However, a series of experimental and epidemiological studies 
have challenged this view. Recent experimental studies have shown that increased uric acid levels 
increase activity of the renin-angiotensin-aldosterone-system,(19) stimulate renal inflammation,(20) 
enhance endothelial dysfunction,(21) and impair renal autoregulation resulting in glomerular (and 
systemic) hypertension.(22) Each of these effects contributes to the initiation and progression of 
renal disease.  In addition, epidemiological studies consistently show that increased serum uric acid 
levels predict renal function decline, independently of other renal or cardiovascular risk factors. 
For example, Hovind et.al. recently showed that increased uric acid is independently associated 
with development of nephropathy, albeit that study was performed in a cohort with type 1 diabetes.
(1) These experimental and clinical studies support the view that uric acid may be involved in the 
pathogenesis of renal disease. 
The most compelling way to evaluate whether uric acid is a marker or risk factor for renal 
disease is to evaluate whether “direct” therapy that lowers uric acid confers renoprotection. A 
couple of studies have highlighted the relevance for renal outcomes of manipulating serum uric acid 
concentrations. It appears that reductions in serum uric acid conferred by allopurinol slow down 
progressive renal function loss in diabetic and non-diabetic patients with chronic kidney disease. 
(23, 24) In addition, treatment of asymptomatic hyperuricemia has been reported to improve renal 
function even in subjects with normal renal function.(25) The results of our analysis showing that 
one-fifth of losartan’s renoprotective effect could be attributed to serum uric acid provide further 
support for the postulate that treatment induced reductions in serum uric acid are associated with 
renoprotection, independent of baseline or changes in renal function. Furthermore, our study 




Serum uric acid increased in the placebo group during the trial and started to increase after 
6 months in the losartan group. A similar trend of changes in serum uric acid over time has been 
observed in the LIFE trial.(11) In the RENAAL trial, GFR fell in the placebo and losartan groups, 
a decline of 5.2 and 4.4 ml/min/1.73m2/year, respectively. We cannot exclude that the longitudinal 
increase in serum uric acid reflects, at least in part, a reduction in GFR over time. An alternative 
possibility is the possible interference of other drugs influencing serum uric acid. The proportion 
of patients receiving a diuretic increased from 58% at baseline to 71% at month 6 and to 84% at 
the time of the primary renal endpoint. The increasing use of concomitant diuretic therapy, which 
increases serum uric acid, could be an alternative explanation for the increase in serum uric acid 
observed during the trial. Since the proportion of patients receiving diuretics was similar between 
the placebo and losartan group at baseline, month 6, and at the end of the trial, it is unlikely that 
concomitant diuretic use has confounded our findings. A final explanation may relate to the effects 
of losartan on uric acid handling during prolonged therapy. In a previous study, the acute effects of 
losartan on uric acid excretion after 3 weeks losartan therapy were less pronounced compared with 
the effects after the first dose was administered.(18) This suggests that the effects of losartan on 
uric acid excretion wane off over time once a new steady state has been achieved.
The data from our study suggest that losartan, registered as a blood pressure lowering drug, 
confers additional renal protection partly through its effect on serum uric acid. Other drugs used 
in renal and cardiovascular risk management appear to lower serum uric acid as well. Fenofibrate, 
registered as a lipid lowering drug, has been shown to decrease serum uric acid. These effects were 
independent of changes in lipid parameters indicating that the drug itself exerts uricosuria.(26) 
Furthermore, fenofibrate has been reported to have certain renal benefits including on albuminuria. 
(27) Another lipid lowering drug, atorvastatin, has been shown to have hypouricemic effects as 
well, irrespective of the drug’s effect on lipid parameters.(28) Whether the effects of these drugs 
on uric acid excretion contribute to their long-term renal and/or cardiovascular protective effects 
are uncertain. On the contrary, drugs that increase serum uric acid may adversely influence renal 
and cardiovascular risk. It is known that diuretics, also registered as blood pressure lowering drugs, 
increase serum uric acid. In this respect, a post-hoc analysis of the SHEP trial demonstrated that 
the cardiovascular protective effect of diuretic therapy was restricted to those individuals in whom 
serum uric acid increased less than 1 mg/dl after one year therapy.(29) Thus, when estimating the 
effects of a drug on renal or cardiovascular endpoints using risk markers, the effect of the drug on 
all risk markers including serum uric acid should be taken into account rather than focusing on the 
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marker the drug is registered for.   
Limitations of this study include the post-hoc nature of the analyses. Although our data 
are derived from a double blind, placebo controlled randomized trial, the analyses according 
to change in serum uric acid are no longer randomized. Although we adjusted for all available 
baseline covariates and changes in covariates, residual confounding cannot be completely excluded. 
Unfortunately, 24-hour urate excretion was not measured in RENAAL participants. This precludes 
the possibility to determine the fractional excretion of uric acid during losartan therapy. The 
reduction in uric acid in subjects with the highest baseline uric acid could indicate a regression to 
the mean phenomenon. However, the fact that we adjusted our multivariate analyses for baseline 
uric acid and the fact that the month 6 uric acid (residual uric acid) remained an independent 
predictor for the primary renal outcome makes this assumption as an explanation for our findings 
less likely. Finally, the results of this study can only be generalized to the, admittedly large, 
population of patients with type 2 diabetes and nephropathy. 
In conclusion, losartan lowers serum uric acid levels, when compared to placebo treatment 
in patients with type 2 diabetes and nephropathy. This change in serum uric acid is independently 
associated with a lower risk of doubling of serum creatinine or end stage renal disease such that 
approximately one fifth of losartan’s renoprotective effect could be attributed to serum uric acid. 
These data indicate that a reduction in serum uric acid observed during the initial months after 
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Aims: To assess the effect of an ARB on serum potassium and the effect of a serum potassium 
change on renal outcomes in patients with type 2 diabetes and nephropathy.
Methods: We performed a post-hoc analysis in patients with type 2 diabetes participating in the 
RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study) 
trial. Renal outcomes were defined as a composite of doubling serum creatinine or end stage renal 
disease. 
Results: At month 6, 259 (38.4%) and 73 (10.8%) patients in losartan and 151 (22.8%) and 34 
(5.1%) patients in placebo group presented serum potassium ≥5.0 mmol/L and ≥5.5 mmol/L, (p< 
0.001) respectively. Losartan was an independent predictor for serum potassium ≥5.0 mmol/L at month 
6 (OR 2.8; 95%CI 2.0-3.9). A serum potassium at month 6 ≥5.0 mmol/L was in turn associated 
with increased risk for renal events (HR 1.22; 95%CI 1.00-1.50), independently of other risk 
factors. Adjustment of the overall treatment effects for serum potassium augmented losartan’s 
renoprotective effect from 21% (6%–34%) to 35% (20%–48%), suggesting that the renoprotective 
effects of losartan are offset by its effect on serum potassium.
Conclusions: In this study we found that treatment with the ARB losartan is associated with a high 
risk of increased serum potassium levels which is in turn associated with an increased risk of renal 
outcomes in patients with diabetes and nephropathy. Whether additional management of high serum 
potassium would further increase the renal protective properties of losartan is an important clinical 
question.
 




Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) in western 
societies. As the prevalence of diabetes is increasing, ESRD accounts for substantial morbidity and 
mortality.(1, 2)
Angiotensin receptor blockers (ARBs) have several important beneficial effects in 
patients with diabetes and nephropathy, such as decreasing systemic blood pressure and reducing 
albuminuria. These effects are related to long-term renal protection.(3, 4) However, these beneficial 
effects are accompanied by a so-called side effect of ARBs, induction of a rise in serum potassium 
levels even leading to hyperkalemia. This may in turn lead to detrimental long-term effects.(5) 
The risk of hyperkalemia is particularly high in patients with diabetes as these patients already 
have reduced aldosterone production secondary to renin deficiency, the so-called hyporeninemic 
hypoaldosteronism syndrome.(6, 7) Diabetes, low renal function and use of renin-angiotensin-
aldosterone system (RAAS) inhibitors are independent factors that increase serum potassium level. 
In combination, these factors pose patients at even higher risk of hyperkalemia.(8)
Increased serum potassium levels are associated with increased risk for cardiovascular (CV) 
morbidity and mortality. Hyperkalemia as a result of ARB therapy has been related to worse CV 
outcomes.(9) However, the relationship between change in serum potassium levels in response to 
RAAS therapy and renal outcomes is not well established. Therefore, we assessed the relationship 
between ARB treatment, serum potassium levels and renal outcomes in patients with type 2 diabetes 
and nephropathy participating in the RENAAL trial (Clinical trials.gov identifier: NCT 00308347).
Methods
Study Design
The RENAAL trial was a multinational, randomized, double-blind trial that compared the effects 
of losartan versus placebo in addition to conventional antihypertensive medication in patients with 
type 2 diabetes and nephropathy. Patients had serum creatinine levels between 1.3 and 3.0 mg/dL (1.5 
to 3.0 mg/dL for males more than 60 kg). The study was performed in 250 centers in 28 countries 
and involved 1513 patients. The study design, the inclusion/exclusion criteria, and the treatment 
protocol have been reported previously.(3, 10) In short, after a 6-week screening phase, patients 
were randomized to either losartan 50 mg (titrated to 100 mg after 4 weeks) or placebo. Additional 
antihypertensive medications (calcium channel blockers, β-blockers, centrally acting agents, 
and diuretics, excluding angiotensin-converting enzyme inhibitors or other angiotensin receptor 
antagonists) were permitted to reach the blood pressure goal of < 140/90 mmHg (systolic/diastolic). 
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All patients signed informed consent before enrollment, and the local Institutional Review Board of 
each participating center approved the study. The mean duration of follow-up was 3.4 years. Blood 
pressure, serum potassium level, serum creatinine and albumin:creatinine ratio were measured at 
1st month, 3rd month, and then every three months until the end of the study.
Change in serum potassium and outcomes
In this study, we performed a post-hoc analysis of all subjects with potassium measurements 
included in the RENAAL trial. We assessed the relationship between serum potassium level and 
renal outcomes in two ways. First, we assessed the relationship between serum potassium and renal 
outcomes at month 6. The month 6 values were chosen since the treatment effects were considered 
to be fully present and relatively few renal events occurred before month 6. The month 6 serum 
potassium level was classified into two categories: <5.0 mmol/L (reference) and ≥5.0 mmol/L.(11) 
We selected this threshold (instead of the clinical accepted value of 5.5 mmol/L) because the risk 
of adverse renal outcomes started to increase from 5.0 mmol/L, and a small number of patients 
reached serum potassium levels ≥5.5 mmol/L in our population. Since a single elevated potassium 
measurement may be an erroneous finding, we also assessed the relationship between persistent 
drug induced serum potassium at month 6 and 9 and its association with renal outcome. These 
subjects were either compared with those with a single elevated serum potassium measurement 
at month 6 or 9, or compared with those without increases in serum potassium above 5.0 mmol/L 
during the first 9 month of follow-up.
In the second approach, we calculated the average serum potassium concentration during 
follow-up and explored the relationship between the average serum potassium level during follow-
up with renal outcomes. The average serum potassium concentration, as well as average levels of 
other relevant covariates was calculated as the mean of the first month and each consecutive third 
month potassium value until the occurrence of the renal event. This approach was chosen since 
it more accurately reflects the risk of a subject to exposure to a high serum potassium load for a 
definite period of time than a single elevated measure. Renal outcomes were defined as a composite 
of doubling serum creatinine (DSCR) or end stage renal disease (ESRD), and as DSCR and ESRD 
individually. All endpoints were adjudicated by a blinded end point committee using rigorous 
guideline definitions.
 




Differences among patient subgroups were evaluated by using Chi-square test or t-test, as 
appropriate. Mean serum potassium level at each visit during follow-up, as well as the proportion 
of patients with month 6 potassium level ≥5.0 mmol/L and ≥5.5 mmol/L was calculated in both 
the losartan and placebo group. To identify the predictors of increased serum potassium at month 
6, a multivariate logistic regression model was used. Baseline characteristics which showed an 
association with serum potassium ≥ 5.0 mmol/L (P<0.2) at univariate analysis were selected for 
the multivariate logistic model. The multivariate logistic model was adjusted for age, treatment 
assignment, serum potassium, diastolic blood pressure, estimated Glomerular Filtration Rate 
(eGFR), month 6 change in eGFR from baseline, urinary albumin:creatinine ratio (ACR), 
prescription of α-blockers, thiazide diuretics, loop diuretics, and hemoglobin. To assess the 
association between change in serum potassium from baseline to month 6 and renal outcomes, 
a multivariate Cox proportional hazard model was used. The linearity of baseline and follow-up 
continuous variables was assessed. If the linearity was not demonstrated, the variable was recoded 
as a categorical variable. In the final Cox model we adjusted for the following baseline variables: 
age, gender, race, treatment, eGFR, follow-up systolic blood pressure, diastolic blood pressure, 
ACR. We checked for an interaction between serum potassium levels at month 6 and eGFR. To 
ensure that our results are not affected by baseline renal function and other important predictors of 
renal outcomes, such as blood pressure and urinary albumin excretion we performed a sensitivity 
analysis in which we matched patients based on their propensity score of developing serum 
potassium ≥ 5.0 mmol/L. The propensity score was obtained by performing a logistic regression 
model with serum potassium ≥ 5.0 mmol/L as an outcome. The risk of renal outcomes was 
presented by hazard ratios (HR) with 95% confidence intervals (95% CI). Analyses were conducted 
with SPSS version 16.0 software.
Results
Serum potassium over time and characteristics of the study population
In the whole population at month 6, 928 (69.4%) patients had a serum potassium <5.0 mmol/L 
(normal value) while 410 (30.6%) patients had month 6 serum potassium ≥5.0 mmol/L (Table 1). 
In the losartan group, mean potassium level significantly increased from 4.59 mmol/L at baseline to 
4.79 mmol/L at month 6, and remained relatively stable during follow-up (Figure 1). In contrast, in 
the placebo group, the mean potassium level decreased gradually from 4.62 mmol/L at baseline to 
4.56 mmol/L at month 6, and remained relatively stable thereafter.
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Figure 1: Mean serum potassium level during follow-up among patients who were assigned to 
receive losartan or placebo
Bars represent standard errors.
The percentage of patients with month 6 serum potassium levels ≥ 5.0 mmol/L and ≥ 5.5 
mmol/L increased from 167 (22.2%) at baseline to 259 (38.4%) and 22 (2.9%) at baseline to 73 
(10.8%) at month 6 respectively in patients on losartan, while in those on placebo it decreased from 
200 (26.2%) to 151 (22.8%) and from 35 (4.6%) to 34 (5.1%) respectively (Figure 2). 
Patients with serum potassium levels ≥ 5.0 mmol/L at month 6 were more likely to have 
higher baseline serum potassium levels, higher ACR, lower diastolic blood pressure and lower 
hemoglobin levels compared to patients with serum potassium <5.0 mmol/L (Table 1). The use of 
losartan was more common while the use of thiazide diuretics and α-blockers was less common in 
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Table 1: Baseline and month 6 characteristics of the whole populationa

















Serum potassium ≥ 5.0 mmol/L, n (%)
Treatment, n (%)
  Losartan
  Thiazide diuretics
  K-sparing diuretics
  Loop diuretics




  Systolic BP, mmHg
  Diastolic BP, mmHg
  Urinary ACR, mg/mmol, median (IQR)



























































Abbreviations are: BP – blood pressure, ACR – albumin-creatinine ratio:
aData are presented as means (SD) unless otherwise indicated
bP<0.05 between patients with K ≥ 5.0 mmol/L and those with K <5.0 mmol/L at month 6
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Figure 2: Proportion of patients with serum potassium ≥ 5.0 mmol/L and ≥ 5.5 mmol/L at baseline 



































































Predictors of incident serum potassium ≥5.0 mmol/L at month 6
In testing in multivariate analysis which baseline parameters are related to increased serum 
potassium ≥5.0 mmol/L at month 6, we found that the strongest baseline predictors were losartan 
therapy (OR 2.81; 95%CI 2.03-3.89) and serum potassium (OR 2.26; 95%CI 1.51-3.37). In 
contrast, a decreased eGFR was associated with an increased risk of high serum potassium. (Table 2). 
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Month 6 change eGFR, ml/min/1.73m2 
Age, yrs
Hemoglobin, mg/dL
Diastolic blood pressure, mmHg
Log transformed ACR, log unit mg/g
Thiazide use
Odds Ratio (95%CI)
2.80 (2.02 – 3.88)
2.30 (1.53 – 3.44)
0.98 (0.97 – 0.99)
0.68 (0.46 – 1.01)
0.75 (0.53 – 1.04)
1.02 (0.99 – 1.05)
1.02 (0.99 – 1.04)
0.94 (0.85 – 1.04)
0.99 (0.98 – 1.01)
1.06 (0.89 – 1.26)

























Presented risk markers were selected for multivariate analysis if an association with serum potassium ≥ 5.0 mmol/L was 
demonstrated in univariate analyses. Risk markers are ordered according the χ2 values.
Month 6 serum potassium and renal outcomes 
Serum potassium level was associated with a higher risk of the composite renal outcome of DSCR 
or ESRD. As observed in Figure 3A, the risk already started to significantly increase from serum 
potassium ≥5.0 mmol/L and further increased at serum potassium ≥5.5 mmol/L during follow-up 
(HR 1.39; 95% CI 1.07-1.80 and HR 1.77; 95% CI 1.22-2.56 respectively). However several other 
factors also explained the progressive loss of renal function such as age, eGFR, and ACR. The most 
important question was therefore whether the progressive nature of renal end points in patients 
with serum potassium ≥ 5.0 mmol/L is independent of other factors, and most importantly, by the 
prevailing renal function, since patients with low eGFR are more prone to develop high serum 
potassium levels. After adjustment for other risk factors, month 6 serum potassium ≥ 5.0 mmol/L 
was associated with a 22% increased risk for developing adverse renal outcomes (HR 1.22; 95% CI 
1.00-1.50). Further analysis revealed that this increased risk was merely attributed to patients with 
persistent drug induced serum potassium ≥ 5.0 mmol/L both at month 6 and month 9 (HR 1.56; 
95%CI 1.09-2.21) (Table 3). 
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Figure 3: Month 6 serum potassium level (3A) and mean serum potassium (3B) and the risk for the 
composite renal endpoint (DSCR or ESRD)
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Table 3: Persistent and single elevated serum potassium ≥ 5.0 mmol/L and their association with 
the risk for doubling of serum creatinine or ESRDa
Risk Factors
Drug induced persistentb serum potassium
 ≥5.0 mmol/L (month 6 and 9)
Singlec elevated serum potassium ≥5.0 












1.54 (1.07 – 2.22)
1.26 ( 0.93 – 1.70)
0.97 (0.96 – 1.00)
2.13 (146 – 3.10)
1.42 (1.01 – 1.99)
1.62 (1.18 – 2.21)
0.96 (0.95 – 0.97)
1.01 (1.00 – 1.02)
0.99 (0.98 – 1.01)
3.75 (3.12 – 4.51)

























a Essentially similar results were obtained for the individual components of the endpoint (data not shown).
b Persistent elevated serum potassium defined as drug induced serum potassium ≥5.0 mmol/l at month 6 and 9.
c Single elevated measurement defined as serum potassium ≥5.0 mmol/l at month 6 or 9.
d There was no interaction between treatment groups and high potassium at month 6 and 9 (p=0.284) indicating that the 
association between high potassium and renal outcome are consistent across both treatment groups.
In the second approach we assessed the association between the mean serum potassium level 
during follow-up with renal outcomes. The relationship between the mean serum potassium level 
during follow-up displayed a similar pattern with renal outcomes as the month 6 serum potassium 
level (Figure 3B). After controlling for potential confounders, the analyses revealed that patients 
who achieved a mean serum potassium ≥ 5.0 mmol/L during follow-up had a 43% higher risk of the 
composite endpoint of DSCR or ESRD (HR 1.36; 95% CI 1.11-1.67). 
The sensitivity analysis in 712 patients matched per propensity score showed similar 
detrimental effects of increased serum potassium ≥ 5.0 mmol/L on renal outcomes (HR 1.32; 




Effect of serum potassium ≥ 5.0 mmol/L on the renoprotection induced by losartan 
To examine to what extent the increase in potassium influences the renoprotective effect afforded 
by losartan, we analyzed the impact of an increase in serum potassium on the losartan treatment 
effect. When the treatment effect on losartan was adjusted for the residual potassium level (last 
potassium level measured prior to the renal endpoint), the treatment effect of losartan on the DSCR 
or ESRD endpoint increased from 21% (6%–34%) to 35% (20%–48%). This suggests that the effect 
of losartan on serum potassium offsets the renoprotective effect of losartan.
      
Discussion
In this study, we showed that treatment with losartan increased the serum potassium concentration. 
We furthermore demonstrated that the occurrence of high serum potassium levels increased the 
risk of adverse renal outcomes and counteract the beneficial renoprotective effects of losartan. The 
increase in the renal risk appeared to be independent of other important renal risk factors, such as 
blood pressure, eGFR and ACR. Thus, although the RENAAL trial has clearly shown that losartan 
is a renoprotective drug, under this protection a renal damaging effect is hiding in those patients 
where losartan induces high serum potassium levels.
The effects of the ARB losartan on serum potassium are in line with other studies. In patients 
with diabetes, either addition or administration of an ARB increases the incidence of hyperkalemia, 
independent of renal function.(8) Also, in patients with heart failure, addition of an ARB or 
aldosterone antagonist to baseline RAAS inhibitor therapy increases the risk of hyperkalemia.
(9, 12) In contrast, in non-diabetic patients addition of RAAS-inhibitors poses a minimal risk of 
hyperkalemia as long as renal function is relatively preserved.(13-17) It appears that the risk of 
hyperkalemia is particularly elevated in patients with underlying predisposing disorders, such as 
diabetes and renal insufficiency, and in patients who receive combined RAAS therapy.
The mechanism via which ARB treatment induces elevations in serum potassium levels has 
already been described.(6) In short, potassium excretion is mainly regulated by serum aldosterone 
and sodium delivery to the distal nephron. Blocking the effects of Angiotensin II by RAAS-
inhibitors decreases aldosterone production and consequently induces hyperkalemia. Patients with 
diabetes are particularly susceptible to the hyperkalemic effects of RAAS-inhibitors as their RAAS-
activity is already suppressed. Several factors may account for this, such as an impaired conversion 
of pro-renin to renin(18) or volume expansion with subsequent increase in circulating atrial 
natriuretic peptide levels and suppression of plasma renin activity.(19)
In previous studies no data are available on the effect of high serum potassium levels on 
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renal outcomes. Our study showed for the first time that increased serum potassium concentrations 
≥ 5.0 mmol/L is associated with a clearly increased risk of DSCR or ESRD, independent of renal 
function and other important predictors of renal outcomes. The pathophysiological mechanism 
whereby increased serum potassium levels affect renal outcomes is not well known. It is likely that 
individuals with persistent drug induced hyperkalemia are resistant against the kaliuretic effects 
of aldosterone. It has indeed been shown that the trans-tubular potassium gradient, as measure 
for aldosterone bioactivity with respect to its kaliuretic response, is decreased in individuals with 
drug induced hyperkalemia despite increased plasma aldosterone levels.(20) Consequently, these 
individuals are continuously exposed to the deleterious effects of aldosterone on renal tissue. 
Another potential mechanism could be that a vicious cycle exits between renal function and 
potassium levels which usually takes place in disorders that affect both tubular dysfunction and 
release of renin. On the one hand, a decrease in renal perfusion and the start of tubulointerstitial 
damage may impair renal potassium excretion, even though renal function is only mildly depressed. 
This may lead to an imbalance in renal potassium/sodium handling which may further damage the 
tubules, thereby subsequently contributing to a further decline in renal function.(7)
Several reports have drawn attention to spurious hyperkalemia (pseudohyperkalemia) 
as a common problem in clinical care.(21, 22) The reasons for spurious hyperkalemia are 
multiple, such as inappropriate phlebotomy technique (e.g. requesting patient to fist clench to 
facilitate venesection), improper sample storage (i.e. cold storage or too long storage causing 
deterioration of the sample specimen) or contamination with anticoagulant from another sample 
(EDTA contamination).(21, 22) As it is unlikely that subjects with a single erroneous potassium 
measurement are at increased risk, we classified patients in those who had persistent high serum 
potassium levels at month 6 and 9. As expected, the increased risk for renal outcomes was 
particularly marked in individuals with high serum potassium at both visit 6 and 9. This implies 
that elevation in serum potassium level needs particular attention and appropriate management 
if it is confirmed at a follow-up visit. In addition, our data on the relationship between the mean 
potassium level during follow-up, which reflects the exposure to a high serum potassium load 
during a definitive period of time more accurately than a single value, and renal outcomes displayed 
a similar association between increased serum potassium and adverse renal outcomes. These results 
are in clear contrast to a recent report from Weir et.al. who suggested that the changes in serum 
potassium concentration observed during RAAS-therapy are unlikely to be clinically significant.
(23) We recommend not down playing modest changes in serum potassium as they independently 
indicate increased risk for renal outcomes in the long-term.
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Hyperkalemia is usually defined by a serum potassium concentration ≥5.5 mmol/L. 
Our results demonstrated a distinct risk of adverse renal events in not only patients with serum 
potassium concentration ≥5.5 mmol/L, but also in patients with potassium concentrations ≥5.0 
mmol/L during follow-up and at month 6. These results have important consequences for clinical 
practice as they indicate that the risk for renal events already starts to increase within ranges that 
are currently considered to be normal. Particular caution is needed when prescribing a second 
RAAS-agent as the combination of RAAS-inhibitors may lead to even higher serum potassium 
levels.(24, 25) In patients with high potassium levels at start of ARB therapy, it may be initiated 
with a low dose, and increased to a higher dose if serum potassium levels do not increase above a 
therapeutic threshold.
Would improved management of high serum potassium levels lead to better renal outcomes 
associated with RAAS blockade? Our study does not directly answer this question. However, when 
we adjusted the treatment effects by the residual serum potassium levels measured prior to the renal 
endpoint the renoprotective effects associated with losartan use markedly improved. It is therefore 
tempting to speculate that management of high serum potassium levels improves the renoprotective 
effects of losartan. Further prospective randomized controlled trials are needed to confirm this 
finding.
Our study has some limitations. First, this is a post-hoc analysis, and as such may be subject 
to confounding. To control for confounding we adjusted for a wide range of clinical variables, 
both at baseline and follow-up. It is nevertheless possible that residual confounding remained 
even in our multivariate adjusted analysis. Also, we performed two additional sensitivity analyses 
matching patients on their eGFR and propensity score to ensure that renal events are independent of 
important predictors of increased serum potassium. Second, although the RENAAL trial included a 
broad range of patients with type 2 diabetes and nephropathy, the findings cannot be extrapolated to 
other populations.
In conclusion, in this study we found that treatment with the ARB losartan is associated with 
a high risk of serum potassium level elevation in patients with type 2 diabetes and nephropathy. 
This elevated serum potassium level is in turn associated with an increased risk of renal outcomes 
and offsets the renoprotective effects of losartan. Whether additional management of elevated 
serum potassium would further increase the renal protective properties of losartan is an important 
clinical question.
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To the Editor: Gonçalves and El Nahas (1) raise interesting comments on our publication 
describing how blockade of the angiotensin I receptor with losartan increases serum potassium 
which is, in turn, associated with an increased risk of renal outcomes in patients with diabetes and 
nephropathy.(2) In their letter, Gonçalves and El Nahas suggest that those patients who developed 
hyperkalaemia were more likely to have pre-existing glomerular or tubulointerstitial damage, which 
could have accounted for the faster progression of renal disease. Although this could, to a certain 
extent, hold true, we believe that such a theory does not explain our findings.
We performed various analyses to ensure that the relationship between increased serum 
potassium and renal outcome was independent of the severity of the underlying renal disease. First, 
we corrected for various renal risk markers, most notably the baseline and change in estimated 
glomerular filtration rate. Second, we conducted a pair-matched analysis selecting patients with 
similar characteristics who did and did not develop hyperkalaemia. Both analyses consistently 
showed that participants in whom serum potassium levels rose had a higher risk of renal disease. 
We therefore consider it unlikely that the greater degree of pre-existing renal injury in individuals 
who developed high serum potassium levels is the main factor responsible for their higher renal 
risk. Nevertheless, since neither glomerular nor tubulointerstitial damage was measured in the 
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, 
we cannot completely rule out the possibility that individuals who developed hyperkalaemia also 
had pre-existing renal damage.
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Further indirect evidence to support our hypothesis that the increase in serum potassium 
is associated with renal outcome stems from an additional analysis showing that adjustment of 
the losartan treatment effect for the residual potassium level (the serum potassium level during 
treatment) improves the overall renoprotective response to losartan. These data suggest that the 
increase in serum potassium during losartan therapy attenuates its long-term renoprotective effect 
and imply that improved management of hyperkalaemia may result in a better renal outcome. 
As mentioned by Gonçalves and El Nahas,(1) it could still be possible that individuals who 
experienced high serum potassium levels received a higher dose of losartan. This hypothesis is, 
however, less likely because the dose of losartan was titrated towards 100 mg/day in almost all 
patients. Gonçalves and El Nahas also suggested that those patients who experienced high serum 
potassium levels could have been more sensitive to a similar dose of losartan.(1) Nevertheless, 
this does not negate the fact that the development of high potassium levels appears to offset the 
renoprotective effect of losartan.
Given that both the short-term responses to losartan in terms of serum potassium levels 
and albuminuria are associated with renal outcomes, either positively (albuminuria) or negatively 
(potassium), Gonçalves and El Nahas (1) highlight the importance of evaluating the relationship 
between both of these responses within individual patients. Such question is of clinical relevance 
since these opposing responses in individual patients may offer important insight into their ultimate 
renal outcome. In this regard, we performed additional analyses to investigate possible correlations 
between responses in serum potassium levels and albuminuria within each individual patient in the 
RENAAL trial. The majority of patients (52.6%) showed a decrease in albuminuria and increase in 
serum potassium levels during treatment with losartan. However, a substantial number of patients 
experienced either reductions in both albuminuria and serum potassium levels (17.7%), an increase 
in albuminuria and a decrease in serum potassium levels (9.6%) or an increase in both variables 
(20.0%). These data illustrate that the change in two variables in response to a single drug varies 
within an individual. The group of patients in whom both albuminuria and serum potassium rose, 
and thus had high residual albuminuria and high serum potassium levels during losartan therapy, 
had a very high risk of renal events, as shown in Fig. 1. However, our findings are based on a post 
hoc analysis, and a prospective evaluation is needed to prove that manipulation of serum potassium 
levels during angiotensin receptor blocker (ARB) therapy may result in improved renal outcomes. 
Nevertheless, these data clearly support the need for monitoring and optimising the response of 
serum potassium levels and albuminuria in individual patients to improve the long-term renal 
protective effects of ARBs.
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Figure 1: Risk for renal events by mean levels of albuminuria (ACR, mg/mmol) and serum 
potassium (mmol/l) during follow-up. The figure shows that both the residual albuminuria and 
serum potassium determine the renal outcome. For conversion of ACR to mg/g multiply by 8.84.




























Based on our observation that losartan treatment is associated with an increase in serum potassium 
levels, which increases renal risk, should we reconsider the continued use of inhibitors of the 
renin–angiotensin–aldosterone system (RAAS)? Gonçalves and El Nahas (1) indeed questioned 
the use of RAAS inhibitors and refer to the recent Ongoing Telmisartan Alone and in Combination 
with Ramipril Trial (ONTARGET), which showed increases in renal risk and hyperkalaemic 
events associated with combined angiotensin-converting enzyme inhibitor (ACEI) and ARB 
therapy compared with the single use of these agents.(3) However, given the proven renal and 
cardiovascular protective effects of ACEIs and ARBs in various populations (including those 
with diabetes and nephropathy),(4, 5) we strongly discourage the discontinuation of these agents. 
Instead, strategies to optimise the effect of a drug on the good surrogates, such as blood pressure 
and albuminuria, and to minimise its effect on the bad surrogates, such as serum potassium, are 
recommended. This approach may attenuate the high renal risk of the growing population of 
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Background: Antihypertensive drugs are developed and registered on the basis of blood pressure 
lowering efficacy combined with safety. However, the long term use has the purpose of preventing 
cardiovascular (CV) morbidity and mortality. Interestingly, antihypertensive drugs have multiple 
off-target effects that may contribute to its efficacy on CV outcomes. The aim of the present analysis 
was to assess whether a multiple parameter risk response outcome (PRO) score, incorporating the 
drug’s short term on-target and off-target effects, better predicts the ultimate renal/CV protection 
than changes in single on-target or off-target effects.
Method: Data were used from subjects with type 2 diabetes and nephropathy participating in the 
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) or 
Irbesartan Diabetic Nephropathy Trial (IDNT) trials. A PRO score was developed by multivariate 
Cox analysis in the placebo arm of the RENAAL trial and was then applied to the baseline and 
month-6 measurements of the ARB treatment arm of the RENAAL trial to predict renal or CV 
risk. The net risk difference at these time-points after correction for placebo effects indicated the 
estimated long-term drug effect. Subsequently, the obtained PRO score was validated in the dataset 
of the IDNT trial.
Results: Changes in single risk markers (e.g. blood pressure) predicted relative risk reductions 
(RRR) significantly different from the actual observed RRR, both for renal (5.7%, vs. 21.8%, 
respectively), and CV outcomes (3.0%, vs. 9.2%, respectively). However, the PRO score accurately 
predicted both renal (RRRpredicted: 30.1 (95% Confidence Interval 10.8 to 49.5) vs. 21.8 (6.5 to 
34.5); p=0.44) and CV treatment effect (RRRpredicted: 9.4 (1.9 to 17.0) vs. 9.2 (-7.6 to 23.6), p=0.98). 
Validation of the PRO score in another diabetes trial (IDNT) accurately predicted the renal 
(RRRpredicted: 26.6 (14.3 to 38.9) vs. 26.0 (6.4 to 41.5) p=0.95) and CV treatment effect (RRRpredicted: 
7.9 (1.3 to 14.5) vs. 11.9 (-8.4 to 28.5) p=0.67).
Interpretation: A PRO score based on month-6 changes in on-target and off-target risk markers 
performs better in estimating ARB effects on hard renal and CV outcomes than any score based on 
changes in single on-target or off-target risk markers.
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Introduction
The ultimate public health goal of antihypertensive therapy is to reduce the risk of renal and 
cardiovascular (CV)  morbidity and mortality.[1] Antihypertensive drugs are however not registered 
based on their efficacy to reduce the risk of renal or CV events, but are developed and registered 
based on their blood pressure lowering capacity. To this end, the effect of the drug on blood 
pressure is established in short-term studies and is subsequently used to estimate the potential 
long-term renal or CV protective effect. This process assumes firstly that the drug effect on blood 
pressure (the on-target risk factor) is directly associated with a reduction in the risk of renal or 
CV complications, and secondly, that the drug does not influence other risk factors (off-target risk 
factors) that influence renal or CV events. The latter assumption has been challenged.
The Losartan Intervention For Endpoint reduction (LIFE) trial showed that the Angiotensin 
Receptor Blocker (ARB) losartan exerted equal blood pressure lowering effects as the β-blocker 
atenolol but conferred superior CV protective effects.[2] The Irbesartan Diabetic Nephropathy Trial 
(IDNT) showed that the ARB irbesartan conferred additional renal protective effects compared 
to the Calcium Channel Blocker amlodipine at equal blood pressure control.[3] Finally, the 
Renoprotection of Optimal Anti-proteinuric Dose (ROAD) trial showed that a supra-maximal dose 
of losartan improves the anti-albuminuric response and conferred markedly more renoprotection 
at similar blood pressure control achieved with losartan at the maximally recommended blood 
pressure dose.[4] These studies suggest that antihypertensive drugs, in these examples ARBs, 
exert additional beneficial effects on renal or CV risk factors, so called off-target effects, which 
contribute to the ultimate long-term effect of the drug. At the other hand, several studies have 
shown that antihypertensive drugs may induce changes in risk factors, such as serum potassium, 
which in fact increase the risk for renal/CV outcome, thus counteracting the beneficial effects of 
these drugs.[5, 6] This implies that only focusing on blood pressure, the on-target risk factor, may 
result in a misleading impression of the drug’s protective efficacy. We hypothesize that knowing the 
short term effect of an antihypertensive on all renal/CV risk markers would allow the composition 
of a response score that would better predict the long term effect of such a drug on the ultimate 
renal/CV outcome. This may have major consequences for drug development, drug registration, and 
individual patient care and highlights the necessity to identify those off-target effects. 
The aim of the present analysis was firstly to identify off-target effects of an ARB and assess 
the impact of the off-target effect on the ARB’s renal/CV efficacy. Secondly, we aimed to construct 
a multiple parameter risk response outcome (PRO) score based on the short-term (6 months) on-
target and off-target effects of ARBs in order to estimate the effect of the drug on long term renal/
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CV morbidity and mortality. Thirdly, we compared the accuracy of ARB efficacy estimates based 
on the multiple PRO score with scores based on single on-target or off-target risk markers. Finally, 
we validated the accuracy of the PRO score in a separate different trial dataset.  
Methods
Study design
Data were used from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist 
Losartan (RENAAL) and IDNT trials. The rationale, study design and outcomes for these trials 
have been previously published and were almost exactly similar.[3, 7-9] In brief, the overall 
aim of the trials was to assess the impact of an ARB on hard renal (primary endpoint) and CV 
outcomes (secondary endpoint) by testing losartan 100 mg/day vs. placebo in the RENAAL trial 
and irbesartan 300 mg/day vs. placebo in the IDNT trial. The IDNT trial also included a Calcium 
Channel Blocker arm which was excluded from the present analysis. Inclusion criteria for both 
trials were presence of type 2 diabetes, nephropathy, and age between 30 and 70 years. Subjects 
with insulin dependent diabetes or renal disease not related to diabetes were excluded in both trials. 
All subjects gave written informed consent. Both trials were approved by local medical ethics 
committees and conducted according to the guidelines of the declaration of Helsinki.
Measurements
In both RENAAL and IDNT, renal and CV risk markers were measured at baseline and at 6 months 
intervals thereafter. All risk markers collected at baseline and month 6 were used to create the 
PRO-score. We selected all measured risk markers at month 6 because we did not know a priori 
which risk markers would change during ARB therapy and secondly to exclude any potential bias 
as a result of risk marker selection. Changes in on-target and off-target risk markers after ARB 
treatment were calculated as the difference between the baseline and the 6-month value. 6-month 
values were chosen because most parameters were available at 6-month and ARB treatment effects 
were considered fully present. Since total cholesterol, hemoglobin, serum albumin, calcium, and 
phosphate were not measured at month 6 in the RENAAL trial, 12-month values were used. 
Renal and cardiovascular outcomes
The primary outcome for the present analysis was defined as a composite of a confirmed doubling 
of serum creatinine from baseline (DSCR) or end-stage renal disease (ESRD). The latter was 
defined as chronic dialysis or renal transplantation. The secondary CV outcome was another 
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endpoint for the present study which was defined in both trials as the composite of myocardial 
infarction, stroke, hospitalization for heart failure, revascularization procedures or death related to 
CV disease. All renal and CV events were adjudicated by an independent blinded committee using 
rigorous definitions. 
Model development
Parameter risk response scores were developed by estimating the risk relation between single or 
multiple risk markers and renal or CV outcomes in the placebo group of the RENAAL trial. The 
single and multiple parameter risk response outcome scores were subsequently applied to the 
baseline and 6-month measurements of the ARB treatment arm to predict renal or CV risk at both 
time points. The difference in the estimated risk at these time-points, adjusted for the difference 
in estimated risk in the placebo arm, indicates the long-term renal or CV risk change conferred 
by ARB treatment. To test the validity of this approach, the single and multiple parameter risk 
response outcome scores were compared with the actual observed renal or CV outcomes of the 
trials. Any model shows too optimistic performance from the dataset from which it is developed. 
The risk response scores were externally validated by developing the scores in the RENAAL trial 
and testing them in the IDNT trial. 
Model evaluation
The methodology to develop the PRO score assumes that the association between risk markers at 
baseline and renal or CV events in the placebo group is similar as the association between single or 
multiple risk markers at 6-month and renal or CV events during ARB therapy. To verify the validity 
of this assumption, we determined whether 6 months ARB treatment modified the association 
between risk markers and renal or CV events. We detected no interaction between any risk marker 
and ARB treatment for the renal or CV outcome as tabulated in table 1. This indicates that ARB 
treatment did not modify the association between single or multiple risk markers and renal or CV 
events. Imputation of missing data yielded essentially similar results as the main analyses.
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Table 1: Absence of significant interaction between risk markers at baseline in the placebo 
group and risk markers at month 6 in the ARB treatment group with renal or CV outcomes in the 
RENAAL trial. Similar results were obtained in the IDNT trial (data not shown)
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Statistical analysis
Mean and standard deviation were provided for 6-month changes in risk markers and statistical 
significance for the between group difference was determined based on a two sided t-test. 
Univariate and multivariate Cox proportional hazard regression was used to determine the 
relationship between baseline risk markers in the placebo treatment arm and renal or CV outcome. 
For subjects who experienced more than one renal or CV event during follow-up, survival time 
to the first relevant endpoint was used in each analysis. Participants were censored at their date 
of death or, for those still alive at the end of follow-up, the date of their last clinic visit before 
the termination of the trials. The multivariate Cox analysis included the following risk markers, 
systolic blood pressure, urinary albumin:creatinine ratio (UACR), potassium, hemoglobin, uric 
acid, HbA1c, total cholesterol, Body Mass Index, calcium, phosphate, and albumin. Bootstrap 
methods were applied, repeating the entire modeling with 1000 independent bootstrap samples, 
to include the variability of the regression coefficients of single and multiple risk scores and renal 
or CV outcomes. To determine the actual observed effect of losartan or irbesartan on renal/CV 
outcomes, the dichotomous treatment variable was used in a Cox regression model and the relative 
risk reduction was calculated as (1- hazard ratio) multiplied by 100%. Bootstrap methods, based on 
1000 replications, were also used to derive the 95% confidence interval of the difference between 
the actual observed and predicted treatment effect. The difference between the predicted and 
observed treatment effect was tested by means of two sided t-tests. We verified normal distribution 
of the predicted treatment effect and performed log-transformation if required. Time-dependent 
Cox regression analysis was used to assess the interaction between risk markers at baseline in the 
placebo group and 6-month risk markers in the ARB treatment group with renal/CV outcomes. 
A two-sided p value of 0.05 indicated the nominal level of statistical significance. Analyses were 
conducted with R 2.10.1 (R Project for Statistical Computing www.r-project.org). 
Results
Baseline characteristics between the ARB and placebo groups in the RENAAL trial was were well 
balanced.[9] Losartan significantly changed multiple off-target renal or CV risk markers beyond 
blood pressure. Relative to placebo, losartan decreased UACR, total cholesterol, hemoglobin, and 
uric acid, it increased potassium, calcium, albumin, and body mass index, while it had no effect on 
HbA1c and phosphate (figure 1). 
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Estimated renal and CV treatment effect by single and multiple parameter risk response outcome 
scores 
During 3.4 years of follow-up 489 renal and 515 CV events were recorded in the RENAAL trial. 
Treatment with losartan resulted in a relative renal risk reduction of 21.8% (95% CI, 6.5 to 34.5%; 
p=0.007) and 9.2% (95% CI -7.9 to 23.6%; p=0.27) relative CV risk reduction, as represented by 
the horizontal line in figure 2A and 2B, respectively. Single risk markers failed to accurately predict 
the renal or CV outcome since they either underestimated or overestimated the actual observed 
drug effect (figure 2A and 2B). The multiple PRO score including all risk markers estimated a long-
term relative renal risk reduction of 30.1% (95% CI; 10.8 to 49.5%), which came close to the actual 
observed relative renal risk reduction (p=0.44), and predicted 9.4% (95% CI 1.9 to 17.0%) relative 
CV risk reduction which was nearly equal to the observed risk reduction (p=0.98 vs. observed 
relative risk reduction; figure 2A and 2B).
Figure 2: Observed and predicted long-term relative renal and cardiovascular risk change (%) 
based on single and multiple PRO scores. Figure A displays the results for renal outcome and 
Figure B displays the results for cardiovascular outcome. The actual observed treatment effect is 
indicated by the solid line. The predicted treatment effect based on single and multiple PRO scores 
are shown by the vertical bars. The PRO score was developed in the RENAAL trial and applied to 



























Observed cardiovascular risk reduction -9%(-24 to +8)
B: PRO score for cardiovascular outcomes developed in RENAAL

























A: PRO score for renal outcomes developed in RENAAL 
and applied to RENAAL
Observed renal risk reduction -22% (-35 to -6)
External validation of the multiple parameter risk response outcome score
To test the validity of the PRO score we applied it to an external separate trial database, the IDNT 
trial, to estimate the treatment effect of the ARB irbesartan on renal and CV outcomes. Irbesartan 
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caused similar directional changes in renal or CV risk markers as losartan although the magnitude 
of these changes varied compared with losartan (figure 1). 
When we entered the irbesartan induced changes in multiple renal or CV risk markers in the 
PRO score, developed in RENAAL, the PRO score estimated a 26.6% (95% Confidence Interval 
14.3 to 38.9%) relative renal risk reduction which was nearly similar to the actual observed relative 
renal risk reduction of 26.0% (6.4 to 41.5%; p=0.95 vs. predicted drug effect; figure 3A). The PRO 
score estimated irbesartan’s CV treatment effect to be 7.9% (1.3 to 14.5%) which did not differ 
from the actual observed CV treatment effect of  11.9% (-8.4 to 28.5 %; p=0.67; figure 3B).
Figure 3: Validation of the PRO score in the IDNT trial. Figure A displays the results for renal 
outcome and Figure B displays the results for cardiovascular outcome. The predicted treatment 
effect is indicated by the dark grey bar and the actual observed treatment effect is indicated by the 
light grey bar. The PRO score is developed in the RENAAL trial and applied to the baseline and 
month 6 measurements of the irbesartan and placebo arm of the IDNT trial.
A: PRO-score validation for renal outcome B: PRO-score validation for cardiovascular outcome

















































Development of the PRO-score in the IDNT trial and application to the irbesartan arm of 
IDNT or losartan arm of the RENAAL trial yielded essentially similar results in that the estimation 
of the observed treatment effect based on the multiple risk response score outperformed scores 
based on single risk markers (Supplement figure). 
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Supplement figure 1: PRO-score development in the IDNT trial and application to the baseline and 
month 6 measurements of the placebo and irbesartan treatment arm of the IDNT trial (figure A renal 
outcomes; figure B cardiovascular outcomes). Validation of the PRO score in the RENAAL trial by 
applying the IDNT developed PRO score to the baseline and month 6 measurements of the placebo 
and losartan treatment arm of the RENAAL trial (figure C renal outcomes; figure D cardiovascular 
outcomes
C: PRO-score for renal outcomes developed in 
IDNT and applied to RENAAL
D: PRO-score for cardiovascular outcomes developed in 
IDNT and applied to RENAAL
A: PRO score for renal outcomes developed in IDNT 

























































Observed cardiovascular risk reduction -12% (-28 to +8)
B: PRO score for cardiovascular outcomes developed in IDNT 
and applied to IDNT

















































We demonstrated that the ARB losartan exerts multiple off-target effects in subjects with type 2 
diabetes and nephropathy. These off-target effects are either positively or negatively associated 
with renal/CV morbidity or mortality. In addition, we showed that only using the short-term change 
in blood pressure, the on-target effect of this antihypertensive agent, cannot capture the ultimate 
effect of losartan on renal/CV morbidity or mortality. In contrast, the PRO score, based on short-
term drug responses of all (available) on-target and multiple off-target risk parameters, is accurate 
in predicting the ultimate long-term drug effect on renal or CV outcomes and performs significantly 
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better than any model based on single on-target or off-target parameters, also in external datasets.  
Often drugs change other risk markers than the one they are targeted to, so called off-
target effects.We demonstrated that the antihypertensive agent losartan does not only lower blood 
pressure, but also reduces urinary albumin excretion, hemoglobin, uric acid, and cholesterol, 
and increases serum potassium, calcium, and albumin. Each of these off-target risk markers are 
associated with renal or CV morbidity or mortality; [5, 10-12] either they decrease or increase the 
risk of these events. It is therefore not surprising that a combination of changes in on-target and 
off-target multiple risk markers more accurately captures the long-term drug effect than changes in 
single on-target or off-target risk markers. 
The blood pressure lowering effect of losartan markedly underestimated the renal/CV 
protective effects of these drugs despite the fact that these drugs are developed and registered as 
antihypertensive drugs. Recent trials have shown that this phenomenon is not limited to ARBs but 
is applicable to other antihypertensive drugs or drug-combinations, [13-16] and even extends to 
other drugs used in CV risk management as well [17-19] as reviewed in the accompanying article.
[20] Taken together, these trials exemplify that the magnitude of renal or CV protection conferred 
with antihypertensive agents, or other drugs used to mitigate CV risk, cannot always be determined 
from their on-target drug effect but depends on their composite effect on all on-target and off-target 
risk markers. 
The PRO score uses multiple risk parameters as is done in many other risk estimation 
engines like the Framingham, UKPDS, or more recent ADVANCE risk engine. What is the 
advantage of the PRO score? Traditional risk engines in patients with diabetes such as the UKPDS 
or the more recent ADVANCE risk engine only include traditional CV risk factors and are based 
on a minimal number of readily available clinical lab parameters to predict individual prognosis.
[21, 22] The PRO score is based on many other parameters that are influenced by drug therapy and 
determine the outcome of the individual, thus increasing the accuracy of the estimates. Indeed, 
models based on blood pressure, Hba1c and cholesterol alone only predicted ~10% renal and 
~2% relative CV risk reductions in the RENAAL trial. In addition, the non-modifiable risk factors 
age and gender account for a major part of future risk in traditional risk engines and obscure the 
value of modifiable risk factors. The PRO-score does not include age and gender as they are non-
modifiable. By not including age and gender a straighter risk relationship between modifiable risk 
markers and outcome is obtained which, in case of drug induced changes, offers a better estimate of 
long-term drug efficacy.
The implications of the present study are multiple. Firstly, a multiple on-target and off-target 
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PRO score enables more accurate drug efficacy assessment on renal/CV morbidity and mortality by 
evaluating the short term effect of the drug on a prefixed set of risk markers. This will then help to 
determine which drugs have the potential to reach the market in early stages of drug development, 
even before long-term trials are conducted. Secondly, in current registration practices, drugs are 
registered based on the target of interest. The on-target effects are well measured, recorded and 
evaluated, whereas the off-target drug effects are usually measured as safety parameters in trials, 
meaning less rigorous measurement and monitoring. A multiple PRO score including on-target and 
off-target drug effects may have the advantage to enable more accurate drug efficacy assessment 
before post-marketing long-term trials are conducted. Finally, the PRO score may offer the 
physician and the patient a better indication on the prescribed drug effect on long-term outcomes. 
This makes the PRO-score particularly relevant for the patient-clinician dialogue and will aid to 
guide the intensity of renal or CV protective drug therapy.
With respect to individual patient care, it should be noted that drug responses within an 
individual may be different.[23, 24]  It has always been assumed that the change in the off-target 
parameter parallels the response in the on-target parameter within an individual. However recent 
studies challenge this dogma. For example, a patient may have a reduction in albuminuria but 
simultaneously experience an increase in blood pressure after initiation of ARB therapy. This 
implies that the composite effect of a drug on multiple parameters in individual patients should be 
established and optimized to improve the ultimate drug effect on clinical outcomes. 
Several aspects of the model should be considered. As with many prediction analyses, the 
model depends on the risk markers measured in the trials. A PRO-score consisting of multiple 
laboratory parameters accurately predicted long-term renal and CV drug effects. Nevertheless, 
we cannot exclude that two additional risk markers that offset each other were not incorporated 
in the model. Secondly, the underlying assumption of the model is that the relation between a risk 
marker and renal or CV outcome is not modified by drug treatment. In other words, the relation 
between a risk marker and outcome in the placebo group is similar to the relation between a risk 
marker and outcome after 6 months ARB treatment. We verified the correctness of this assumption 
in our analyses. Finally, the accuracy of the PRO score depends of the background database such 
as its size, event rate, its accuracy, and the variation in the levels of multiple risk markers. The 
current analyses were derived from the placebo arm of the RENAAL trial. This can be improved 
by increasing the placebo treated background database. The PRO score is only applied to ARB 
treatment in patients with diabetes and nephropathy. No inferences can be made about the 
performance of the score to predict long-term effects of other drugs in other disease areas.
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The PRO-score is generated from landmark clinical trials conducted in patients with diabetes 
and nephrology. To base the score on individual patient data from these trials is helpful as the 
cohort is large and has good follow-up increasing the precision of risk estimates. Furthermore, 
the trials were conducted in various countries increasing international representation. Some 
limitations should be addressed as well. The current analysis is a retrospective analysis and requires 
confirmation in a prospective study. The trials were not sufficiently powered to detect statistically 
significant treatment effects on CV outcomes compromising the precision of the observed and 
predicted CV treatment effects. 
In conclusion, measuring only the short-term blood pressure effect of ARB treatment, the 
on-target parameter, may result in misinterpretations in estimating the long-term renal and CV 
protective effect. This can have major impact on society, individual patients, and drug registration. 
The PRO score based on multiple on-target and off-target risk markers is accurate in predicting the 
long-term outcome of ARB in patients with diabetes and nephropathy.
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Patients with diabetes and nephropathy are prone to develop renal or cardiovascular complications. 
(1, 2) Given the increasing prevalence of diabetes in combination with the relentless course of the 
disease new drugs are needed to mitigate the burden of this disease. Unfortunately, despite increased 
investments in drug development, increased knowledge, and improved methods to discover new 
drug targets, no new drugs have become available over the last decade that reduce the risk of renal 
complications. Although attempts have been made to discover novel drugs, and a number of them 
have indeed been tested in the clinical setting, it appears that during late stage drug development we 
fail to prove them efficacious. Indeed, recent data show that in diabetes 13% of drugs do not reach 
the market because of inefficacy or safety issues during late stage drug development.(3) Apparently, 
we are not very successful to correctly estimate drug efficacy in early stages of development.
The drug development (and registration) process in renal disease management involves the 
estimation of long-term efficacy and safety. During drug development, the effect of the drug on 
the risk factor the drug is developed for (such as blood pressure for an antihypertensive drug or 
HbA1c for an oral glucose lowering drug) is used to estimate the drug’s efficacy and to calculate 
the expected long-term renal protection. The drug effect on these renal risk factors is established 
during short-term studies, generally up to 6 months of duration. To confirm the estimated long-term 
efficacy and safety, the short-term drug evaluation is followed by a post-marketing hard-outcome 
study looking at clinical meaningful outcomes. The latter thus requires large randomized controlled 
clinical trials.
Recently, numerous drugs have failed to afford renoprotection or appeared to be even 
harmful despite the drug was beneficial on the target (risk factor) it was developed for. Thus, the 
drug was not delivering what it was thought to do. For example, avosentan reduced blood pressure 
(and proteinuria) but increased the risk of cardiovascular events, especially congestive heart failure.
(4) Likewise, rosiglitazone was withdrawn from the market because of excess of cardiovascular 
events despite it lowers HbA1c, the on-target risk factor.(5, 6) These examples unambiguously 
illustrate the failure to use the short-term effect of a drug on the on-target risk factor to estimate the 
effect of the drug on hard clinical meaningful renal outcomes and highlight the inability to correctly 
predict drug efficacy.
Also in patients with diabetes and nephropathy, the reduction in blood pressure induced by 
Angiotensin Receptor Blockers (registered as anti-hypertensive drugs and the mainstay of therapy 
in these patients next to blood glucose lowering) does not explain the long-term renoprotective 
effect. The Reduction of Endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin 
II Antagonist Losartan (RENAAL) and Irbesartan Diabetic Nephropathy Trial (IDNT) have 
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shown that losartan and irbesartan respectively delay the progression of renal disease in patients 
with diabetes and nephropathy.(7, 8) Although both losartan and irbesartan are registered as 
antihypertensive drugs, the renoprotective effect of these agents appears to be independent of 
blood pressure. This indicates that these drugs have other effects, so called off-target effects, which 
contribute to the renoprotective effects of these drugs. 
These observations form the basis of the studies conducted in this thesis. In this thesis we 
investigated which off-target effects ARBs exert and the relationship between these off-target 
effects with hard renal outcomes in patients with type 2 diabetes and nephropathy. The ultimate aim 
of the thesis was to combine the on-target and different off-target effects of a single drug into a so 
called multiple parameter risk response score in order to accurately predict drug efficacy on hard 
renal outcomes after short-term (6 months) drug treatment.
Off-target effects of various drugs in patients with diabetes
Throughout the thesis we explored the effects of a drug on off-target risk markers. Chapter 
2 provides an overview of the effects of various drugs on novel risk/biomarkers and the 
relationship between (drug induced) off-target changes in risk/biomarkers and long-term renal and 
cardiovascular outcome in patients with diabetes. In this chapter we showed that the short-term 
reduction in albuminuria, transforming growth factor-beta, and N-terminal pro-B–type natriuretic 
peptide (NT-proBNP) induced by inhibitors of the RAAS were associated with a risk change in 
renal and cardiovascular outcomes. These data indicate that RAAS inhibition with ACEi or ARB 
exerts multiple effects on different renal and cardiovascular risk markers which subsequently can 
change the risk of renal or cardiovascular events. 
Off-target effects of ARBs and their relationship with renal outcome
Uric Acid
Serum uric acid (SUA) has emerged as a renal risk marker. Increased SUA has been shown to 
predict the risk of hypertension, diabetes mellitus, and cardiovascular disease.(9-11) Previous 
studies have shown that losartan lowers SUA. This hypouricemic effect appears to be largely 
mediated through reductions in the level of human urate transporter 1 (URAT1) and decreased net 
urate reabsorption in the proximal tubule.(12) In chapter 3 we investigated whether losartan exerts 
off-target effects on uric acid in patients with type 2 diabetes and nephropathy and whether the 
reduction in uric acid is associated with renoprotection. Indeed, losartan treatment attenuated the 
rise in SUA levels compared with placebo. The reduction in SUA appeared to be associated with 
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renal events so that per 0.5 mg/dL decrement in SUA during the first 6 months the risk for doubling 
of serum creatinine or ESRD reduced by 6% (95%CI 10-3) This association was statistically 
significant, even after adjustment for a broad range of known renal risk factors. Interestingly, the 
effect of losartan on SUA explained approximately 20% of its overall renoprotective effect. These 
data indicate that the off-target effect of losartan on SUA contributes to its renoprotective effect and 
suggest that SUA is a modifiable risk marker for renal disease, at least in patients with diabetes and 
nephropathy.
Serum potassium
Although ARBs have several beneficial effects in patients with diabetes and nephropathy, such as 
decreasing systolic blood pressure, albuminuria, and serum uric acid,(13, 14) they also have other 
effects that may be related to increased renal risk Treatment with Angiotensin Receptor Blockers 
is associated with a rise in serum potassium, secondary to decreased aldosterone secretion and 
impaired potassium excretion. These effects are particularly pronounced in patients with diabetes 
and nephropathy. In chapter 4a we confirm that treatment with losartan increased serum potassium 
concentration, which was in turn associated with an increased risk of renal outcomes and counteract 
the renoprotective effects of losartan. The increase in renal risk appeared to be independent of 
other important renal risk factors, such as blood pressure, eGFR, and albuminuria. Thus, although 
losartan has clearly been shown to be a renoprotective drug, under this protection a renal damaging 
effect is hiding in those individuals in whom losartan induces high serum potassium levels. 
The data reported in chapter 4a indicate that in order to predict the effect of a drug on hard 
outcomes by using changes in risk markers one should not only evaluate the risk markers that are 
associated with renoprotection but also take into account the markers that are adversely associated 
with hard renal outcomes. Currently in drug development, the change in potassium is registered 
as a safety issue and not as an efficacy issue. However, since the ARB induced change is serum 
potassium affects its renoprotective efficacy, the change in serum potassium should also be included 
in efficacy determination and not only separately analyzed as a safety issue. In response to a letter 
to the editor we provided additional data in chapter 4b demonstrating that the relationship between 
increased serum potassium and renal outcome was independent of the severity of the underlying 
renal disease. Additionally, in this chapter we provided detailed insight in the different patterns 
of response in albuminuria and serum potassium in individual (sub-group of) patients and their 
relationship with renal outcomes. It appeared that the response in albuminuria and serum potassium 
to ARB-therapy was discordant within an individual in a large proportion of patients. This indicates 
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that within a patient could not response in terms of albuminuria (no reduction) but had an increase 
in serum potassium, or vice versa, responded in terms of albuminuria (thus had a decrease in 
albuminuria) but no response in serum potassium. The group of patients in whom both albuminuria 
and serum potassium rose, and thus had high residual albuminuria and high serum potassium 
levels during losartan therapy, had a very high risk of renal events. This warrants strategies that 
optimize the effect of a drug on the good surrogates, such as blood pressure and albuminuria, and 
to minimize its effect on the bad surrogates, such as serum potassium, in individual patients. This 
approach may attenuate the high renal risk of the growing population of patients with diabetes and 
nephropathy.
Integrating the on-target and off-target effects of ARBs to better predict the renoprotective 
effects 
In the chapters 2 to 4b we have shown that ARBs have many other effects than blood pressure 
lowering alone. The question we addressed in chapter 5 was whether we could use these off-
target drug effects to better estimate the ultimate drug effect of an ARB on hard renal outcomes. 
We therefore set out to construct a multiple parameter risk response score that incorporates the 
on-target and off-target effects of ARBs. In this chapter we showed that a multiple parameter risk 
response score based on 6-month changes in on-target and off-target risk markers can be used to 
accurately predict the long-term effect of an ARB on hard renal and CV outcomes and performs 
better than any score based on changes in single risk markers.
Conclusion and future perspectives
In this thesis, the multiple effects of ARBs on various renal risk factors were investigated and the 
relationship between changes in these risk factors following ARB therapy on hard renal outcomes 
were analyzed. We have shown that off-target changes in risk parameters contribute to the drug’s 
efficacy either in a positive (enhancing the ultimate drug effect) or negative (blunting of the 
ultimate drug effect) way. An integrated multiple parameter risk response outcome score, including 
the on-target and off-target drug effects, was very accurate in predicting drug efficacy on hard renal 
outcomes. This indicates that an integrative approach, establishing the drug effect on all renal risk 
factors, is warranted to assess drug efficacy in the absence of hard outcome data. This conclusion 
has important implications for  drug development, drug registration, and individual patient care. 
1.  From a drug development perspective, one should not only focus on the on-target risk factor 
but also consider the effect of a drug on multiple off-target parameters as drug induced changes in 
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these parameters may enhance or blunt the ultimate drug effect. Early accurate assessment of drug 
efficacy by using the integrated drug effect on all renal risk markers will enable the drug developer 
to establish which drug has the potential to reach the market in early stages of development and 
should be further developed as well as it likely prevents lack of post marketing efficacy or safety on 
hard outcomes. Therefore, a better efficacy estimation of long-term drug effects in early phases of 
drug development will result in lower drug-attrition rates, less patient exposure to ineffective drugs, 
and tremendous cost savings.
2.  From the regulatory perspective, improved estimation of long-term drug effect will aid to 
well inform regulatory decisions about novel drugs. In current registration practices, drugs are 
registered based on the target of interest for which one marker is tested and on being a safe drug 
for which multiple off-target markers are tested. The off-target drug effects are usually separated 
from the safety (or off-target) discussion. However, we advocate to change our thinking of drugs 
in terms of efficacy and safety, but much more about effects that are wanted and unwanted and that 
all effects contribute to the ultimate outcome. We advocate to classify single drugs that are aimed 
at long term renal/CV protection as such: renal/CV protective drugs instead of considering them 
as antihypertensive or oral glucose lowering drugs which implies that they only decrease blood 
pressure or glucose. This would require an integrated algorithm involving all relevant renal/CV risk 
markers: the proposed integrated multiple parameter risk response outcome score which likely aids 
to better drug efficacy assessment and well informed regulatory decisions on novel drugs. 
3.  From the patient-clinician point of view, using an integrated score of on-target and off-target 
parameters in clinical practice to determine long-term drug effects in an individual patient score 
may offer the physician and the patient a better indication on the prescribed drug effect and will aid 
to guide the intensity of renal or CV protective drug therapy.
The analyses we have conducted are based on already finished trials. Therefore, our findings need to 
be replicated in ongoing trials to confirm the validity and predictability performance of our multiple 
risk parameters modeling approach. Validation studies are currently ongoing. If our results can be 
confirmed in prospective studies, they may contribute to a shift in our thinking how drugs should be 
developed and monitored in clinical practice.
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Patiënten met diabetes lopen een hoog risico op het ontwikkelen van nierziekte. In het licht van de 
toegenomen prevalentie en daarmee samenhangend toegenomen prevalentie van nierziekte zijn er 
nieuwe geneesmiddelen en nieuwe behandelstrategieën noodzakelijk om de prognose van patiënten 
met diabetische nefropathie te verbeteren. Echter, ondanks onze toegenomen kennis omtrent de 
pathofysiologie van diabetes en verworven inzichten in het ontwikkelen van geneesmiddelen 
zijn er de laatste jaren geen nieuwe geneesmiddelen voor deze patiëntengroep ontwikkeld. 
Helaas blijkt nog steeds dat ongeveer 13% van alle geneesmiddelen die het eindstadium van het 
geneesmiddelontwikkelingsproces halen uiteindelijk niet op de markt komt. De meest voorkomende 
oorzaak is dat het geneesmiddel niet effectief is. Blijkbaar zijn wij dus niet in staat om op juiste 
wijze de effectiviteit van een geneesmiddel in een vroeg stadium van ontwikkeling in te schatten. 
Het geneesmiddelontwikkelingsproces (en geneesmiddelregistratieproces) beoordeelt de 
effectiviteit en veiligheid van het te ontwikkelen geneesmiddel op basis van risicofactoren voor 
nierziekte en hart- en vaatziekte. Tijdens de ontwikkelingsfase wordt de effectiviteit van een 
geneesmiddel beoordeeld op het effect op de risicofactor waarop het geneesmiddel is ontwikkeld 
(zoals bloeddruk voor een bloeddrukverlagend geneesmiddel en cholesterol voor een statine). Dit 
effect op de zogenaamde on-target risicofactor wordt gebruikt om uiteindelijk een inschatting te 
maken van het effect van het geneesmiddel op klinische relevante eindpunten. 
In de laatste jaren is er van verschillende geneesmiddelen geen toegevoegde waarde 
aangetoond bovenop het huidige arsenaal van geneesmiddelen ondanks dat deze nieuwe 
middelen gunstige effecten hebben vertoond op risicofactoren voor nierziekte. Dit houdt in dat 
het geneesmiddel uiteindelijk niet het veronderstelde effect opleverde wat gedacht werd op basis 
van de effecten van het geneesmiddel op de risicofactor. Zo werd bijvoorbeeld avosentan (een 
geneesmiddel dat bloeddruk en proteinurie verlaagt) in verband gebracht met een hoger risico op 
hartfalen en werd rosiglitazone van de markt gehaald vanwege het induceren van hartfalen ondanks 
dat het HbA1c verlaagde. Deze voorbeelden laten zien dat het huidige geneesmiddelontwikkelingst
raject, dat gebaseerd is op het inschatten van de effectiviteit van een geneesmiddel gebaseerd op het 
geneesmiddeleffect op slechts één risicoparameter, tekortschiet. 
Geneesmiddelen die een belangrijke bijdrage vormen in het verlagen van eindstadium 
nierziekte in patiënten met diabetisch en nierziekte zijn de bloeddrukverlagende angiotensine 
II antagonisten. Uit verschillende studies blijkt echter dat de mate van bloeddrukverlaging 
geïnduceerd door deze geneesmiddelen slechts in geringe mate de effectiviteit van deze 
geneesmiddelen verklaart. In de RENAAL en IDNT studies werd aangetoond dat losartan en 




ten opzichte van placebo behandeling. Hoewel zowel losartan als irbesartan geregistreerd zijn als 
antihypertensiva blijkt dat de mate van bloeddruk verlaging in deze studies slechts een zeer geringe 
bijdrage vormden voor de mate van nierbescherming. Dit suggereert dat geneesmiddelen blijkbaar 
andere effecten vertonen (off-target effecten) die een bijdrage leveren aan de mate van risicio-
bescherming op harde klinische eindpunten. 
Deze observaties vormden de basis voor het onderzoek dat beschreven is in dit proefschrift. 
In dit proefschrift worden de verschillende ‘off-target’ effecten van angiotensin II antagonisten 
onderzocht en de relatie met nierziekte beschreven. Het uiteindelijke doel van dit proefschrift is om 
een risico score te ontwikkelen die zowel de on-target als off-target effecten van een geneesmiddel 
omvat. Dit als doel om een betere inschatting te maken van de effectiviteit van een geneesmiddel 
op harde klinische eindpunten. 
Off-target geneesmiddeleffecten in patienten met diabetes
In hoofdstuk 2 wordt een overzicht gegeven van verschillende geneesmiddelen die gebruikt 
worden in de behandeling van type 2 diabetes. In dit hoofdstuk worden de verschillende off-target 
effecten van deze middelen beschreven en hoe zij in relatie staan met klinische eindpunten. Zo is 
bijvoorbeeld het NT-proBNP verlagende effect van geneesmiddelen die het renine-angiotensine-
aldosterone-systeem remmen geassocieerd met een verminderd risico op nierziekte en hart- en 
vaatziekte. 
Off-target effecten van Angiotensine-II-antagonisten en relatie met nierziekte
Urinezuur
Urinezuur wordt in toenemende mate gezien als een belangrijke risicofactor in de ontwikkeling en 
progressie van nierziekte. Voorgaand onderzoek heeft aangetoond dat losartan urinezuur verlaagt. 
Het effect van losartan op de URAT transporter blijkt hierbij een belangrijke rol te spelen. Of de 
verlaging van urinezuur door losartan ook een bijdrage levert aan het nierbeschermende effect van 
losartan was onbekend. Dit werd in hoofdstuk 3 onderzocht. Inderdaad bleek dat een verlaging van 
0.5 mg/dL in urinezuur door losartan geassocieerd is met een 6% risicoverlaging op het ontwikkelen 
van eindstadium nierziekte. Deze relatie was statistisch significant en onafhankelijk van andere 




Hoewel angiotensine-II-antagonisten gunstige effecten uitoefenen in patiënten met diabetes hebben 
zij echter ook effecten die het risico op nierziekte kunnen verhogen. Het hyperkalemisch effect 
van deze middelen zou het risico op nierziekte kunnen verhogen. Het risico op hyperkalemie 
geïnduceerd door een angiotensine-II-antagonist is juist verhoogd in patiënten met diabetes en 
nierziekte. In hoofdstuk 4 bevestigden wij dat losartan kalium spiegels verhoogt. Deze verhoging 
in kalium was vervolgens onafhankelijk geassocieerd met een verhoogd risico op eindstadium 
nierziekte. Interessant is de bevinding dat correctie van het behandeleffect van losartan op nierfalen 
voor het effect van losartan op kalium het beschermende effect van losartan met maar liefst 40% 
laat toenemen! Dit suggereert dat een deel van de effectiviteit van Angiotensine-II-antagonisten 
te niet wordt gedaan door het effect van deze geneesmiddelen op kalium. Dus, hoewel het 
onomstotelijk is vastgesteld dat losartan een nierbeschermende werking uitoefent blijkt dat onder 
deze bescherming een schadelijk effect schuil gaat dat de effectiviteit van losartan deels teniet doet. 
Sommigen hebben zich afgevraagd of de relatie tussen een verhoogde kalium spiegel en 
eindstadium nierziekte niet het gevolg is van onderliggend nierschade. Naar aanleiding van een 
‘letter to the editor’ hebben wij in hoofdstuk 4b extra analyses uitgevoerd om aan te tonen dat de 
relatie tussen kalium en eindstadium nierziekte niet wordt bepaald door onderliggend nierschade. 
Integratie van on-target en off-target geneesmiddeleffecten om de nierbeschermende effecten 
van angiotensine-II-antagonisten beter te voorspellen
In hoofdstuk 2 tot en met 4 hebben wij verschillende off-target effecten van Angiotensine-II-
antagonisten beschreven. In hoofdstuk 5 integreerden wij deze effecten in één risico score om 
een betere inschatting te maken van geneesmiddeleffectiviteit. We laten in dit hoofdstuk zien dat 
een score die zowel de on-target als de off-target effecten van een geneesmiddel bevat de beste 
schatting oplevert omtrent de effectiviteit van een geneesmiddel in het voorkomen van nierziekte en 
hart- en vaatziekte. 
Conclusie en toekomstperspectief
In dit proefschrift is aangetoond dat off-target geneesmiddeleffecten van angiotensine-II-
antagonisten een belangrijke bijdrage kunnen leveren in de effectiviteit (zowel in positieve als 
in negatieve zin) van een geneesmiddel in het voorkomen van nierziekte. De integratie van alle 
off-target effecten met het on-target geneesmiddeleffect levert uiteindelijk de beste voorspelling 




Deze bevinding heeft belangrijke consequenties voor zowel geneesmiddelontwikkeling, 
geneesmiddelregistratie en individuele patiëntenzorg. 
1.  Wat betreft geneesmiddelontwikkeling is het van groot belang om in een vroeg stadium inzicht 
te krijgen in de effectiviteit van het geneesmiddel op klinische eindpunten. Op basis van deze 
inzichten kunnen besluiten worden genomen om al dan niet het ontwikkelingsproces door te zetten 
en kunnen grootschalige geneesmiddeltrials op een efficiënte manier worden opgezet. 
2.  Vanuit het oogpunt van geneesmiddelregulering zal een betere voorspelling van het 
geneesmiddeleffect op klinische relevante eindpunten de regelgevinginstantie kunnen helpen om 
juiste beslissingen te nemen of nieuwe geneesmiddelen op de markt kunnen worden toegelaten. 
Op dit moment worden off-target geneesmiddeleffecten niet meegewogen in de discussie omtrent 
geneesmiddeleffectiviteit maar worden zij apart beoordeeld als veiligheidsparameters (denk hierbij 
bijvoorbeeld aan kalium). Wij zijn voorstander om alle off-target effecten mee te nemen in de 
beoordeling van geneesmiddeleffectiviteit en in dit opzicht zo weinig mogelijk scheiding aan te 
brengen tussen geneesmiddeleffectiviteit en veiligheid. Om de effectiviteit van een geneesmiddel 
op basis van risico factoren te beoordelen is een geïntegreerd algoritme noodzakelijk, de door ons 
ontwikkelde score kan in dit opzicht gebruikt worden. 
3.  Tot slot kan vanuit het perspectief van individuele patiëntenzorg een geïntegreerde score 
zowel de patiënt als de behandelaar een beter perspectief geven omtrent de effectiviteit van een 
geneesmiddel en zou van dienst kunnen zijn in het optimaliseren van de behandeling voor de 
individuele patiënt. 
De resultaten besproken in dit hoofdstuk zijn verworven uit inmiddels afgeronde trials. De 
resultaten (met name de on-target / off-target risico score) moeten nu bevestigd en gevalideerd 
worden in geneesmiddeltrials die op dit moment lopende zijn. Indien de resultaten besproken in 
dit proefschrift gerepliceerd en gevalideerd worden kan dit een belangrijke verandering te weeg 
brengen in de manier waarop geneesmiddelen worden ontwikkeld en beoordeeld; namelijk niet 
richten op een enkele risicofactor maar op basis van een geïntegreerd algoritme dat alle effecten 
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